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1. Introduction 
Telemedicine, the use of telecommunications technology to remotely diagnose 
and treat patients, has the potential to address provider shortages and improve access to 
care for patients, and lower health care costs and expenditures across public and private 
coverage populations (MedPAC, 2016). Recent federal and state legislation expanding 
coverage and increasing provider reimbursement for telemedicine services, combined 
with investments in telemedicine technologies by public and private entities, have led to 
expansions in the use of telemedicine services (MedPAC, 2018).  
However, work to date has focused on telemedicine use for a single insurer and 
has mostly estimated cross-sectional comparisons of health care use and outcomes 
between telemedicine users and non-users. This dissertation expands upon prior empirical 
research investigating telemedicine by characterizing the growth in different types of 
telemedicine services in Minnesota. By using the Minnesota All Payer Claims Database 
(MN APCD), I examine various covered populations, and investigate how insurance 
coverage expansions and state policies affected telemedicine use and their impacts on 
patient outcomes. The first chapter has already been published, and the other two 
chapters are publication-formatted papers. 
The first chapter of the dissertation investigates how telemedicine is being used 
across the state of Minnesota, with an emphasis on categorizing how different types of 
telemedicine visits are being used by different coverage and geographic populations (Yu, 
Mink, Huckfeldt, Gildemeister, & Abraham, 2018). Specifically, my co-authors and I use 
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the MN APCD to examine the patterns of telemedicine use in the state from 2010 to 2015 
(Yu et al., 2018).  
The second chapter estimates the association of convenience care telemedicine 
services, or direct-to-consumer (DTC) telemedicine visits and health care utilization, 
quality, and spending outcomes. This paper seeks to understand whether DTC 
telemedicine may serve as a substitute for in-person care for certain types of services and 
conditions. Using the 2009-2014 MN APCD, my co-authors and I examine DTC use for 
urinary tract infections (UTIs) for non-elderly females with commercial insurance in 
Minnesota. We employ a quasi-experimental framework to compare changes in patient 
outcomes for individuals with UTIs among those with insurance from payers introducing 
DTC telemedicine coverage relative to those with insurance from payers who did not. 
Additionally, we examine changes in population-level utilization of health services for 
UTIs to determine the extent to which DTC telemedicine services may displace 
traditional in-person health services.  
In the third chapter, I use the MN APCD from 2010 to 2016 to assess whether 
telemedicine visits increased after the enactment and implementation of a statewide 
parity law in 2015 and 2016 respectively, which mandated that telemedicine services are 
paid at the same rates as in-person services for Medicaid enrollees. The Medicaid 
population in MN includes both Medical Assistance, which is Minnesota’s state Medicaid 
program for people with incomes at or below 138% of the federal poverty level (FPL) 
and MinnesotaCare, a program for Minnesotans with incomes at or below 200% of the 
FPL ("MinnesotaCare: FAQS," 2019). I examine both the growth in the volume and the 
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types of telemedicine services within the Medicaid population in Minnesota, as well as 
the differential growth in the Medicaid population relative to a comparison group of 
enrollees.  
Taken together, these chapters provide insight about the developing landscape of 
telemedicine provision and use. This work makes a novel contribution to the literature by 
1) leveraging a unique dataset to examine the growth in telemedicine services, 2) 
examining follow-up outcomes associated with a telemedicine visit, and 3) evaluating 
expansions in health care utilization associated with telemedicine policies. The studies 
presented in this dissertation are some of the first to produce a comprehensive account of 
the growth in telemedicine use across payers, as well as to employ a quasi-experimental 
framework to examine the association between telemedicine use and patient-level 
outcomes, and whether telemedicine reimbursement policies can facilitate the growth of 
telemedicine services, particularly within non-metropolitan and underserved populations. 
The evidence produced by these papers can be used by policymakers, providers, 
and insurers to consider different applications of telemedicine use in various patient 
populations, to examine other barriers and facilitators of telemedicine provision, and to 
extend these analyses to explore other conditions and services for which telemedicine is 
an effective substitute for in-person care. 
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2. Chapter 1: Population-Level Estimates of Telemedicine Service Provision Using 
An All-Payer Claims Database 
 
Jiani Yu, Pamela J. Mink, Peter J. Huckfeldt, Stefan Gildemeister, and Jean M. 
Abraham 
 
Published in Health Affairs 
 
Yu, J., Mink, P. J., Huckfeldt, P. J., Gildemeister, S., & Abraham, J. M. (2018). Population-
Level Estimates Of Telemedicine Service Provision Using An All-Payer Claims 
Database. Health Affairs, 37(12), 1931-1939. 
 
 
2.1. Synopsis 
In recent years state and federal policies have encouraged the use of telemedicine by 
formalizing payments for it. Telemedicine has the potential to expand access to timely 
care and reduce costs, relative to in-person care. Using information from the Minnesota 
All Payer Claims Database, we conducted a population-level analysis of telemedicine 
service provision in the period 2010–15, documenting variation in provision by coverage 
type, provider type, and rurality of patient residence. During this period the number of 
telemedicine visits increased from 11,113 to 86,238, and rates of use varied extensively 
by coverage type and rurality. In metropolitan areas telemedicine visits were primarily 
direct-to-consumer services provided by nurse practitioners or physician assistants and 
covered by commercial insurance. In nonmetropolitan areas telemedicine use was chiefly 
real-time provider-initiated services delivered by physicians to publicly insured 
populations. Recent federal and state legislation that expanded coverage and increased 
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provider reimbursement for telemedicine services could lead to expanded use of 
telemedicine, including novel approaches in new patient populations. 
 
2.2. Introduction 
 
With advances in telecommunications technologies, health care providers are 
increasingly able to remotely diagnose and treat patients with a variety of medical 
conditions through telemedicine. In the United States the overall use of telemedicine 
remains low but has been increasing over time. For example, among fee-for-service 
Medicare enrollees, telemedicine use increased from 0.6 to 9.5 visits per 1,000 
beneficiaries between 2006 and 2016 (MedPAC, 2018).Telemedicine is increasingly 
viewed as a way to potentially improve patients’ access to timely medical care and the 
quality of care, as well as reduce costs (Dixon BE, 2008). 
Different types of telemedicine exist, each having unique uses and potential 
effects on care processes. Three major categories of telemedicine are patient-initiated 
consultations outside of a clinic with providers via structured messages, or video; real-
time provider-initiated consultations with a remote provider via video-conferencing, with 
or without the patient present; and non–real time (asynchronous) provider-initiated 
consultations between two or more providers (MedPAC, 2016b, 2018). By provider we 
mean a physician, nurse practitioner, physician assistant, psychologist, or other clinician. 
Another category of telemedicine is remote patient monitoring, which allows providers to 
collect health data from patients, particularly those with complex care needs, 
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electronically. Because of the limited coverage of remote patient monitoring services in 
Minnesota and nationally during the study period, we excluded this category from our 
analysis.  
Patient-initiated consultations, also known as direct-to-consumer telemedicine, 
typically focus on acute primary care services and are often provided by a third-party 
company rather than a patient’s primary care provider (MedPAC, 2018; Uscher-Pines et 
al., 2016). Real-time provider-initiated consultations are live audiovisual communications 
initiated by an originating provider with a remote provider, during which a patient may or 
may not be present. Widely used examples include telemental health services, in which a 
patient receives treatment in their home clinic from a distant mental health specialist, and 
telestroke services, in which a remote specialist supervises stroke care for a patient via 
teleconference (MedPAC, 2018; Mehrotra et al., 2017). Finally, asynchronous, or “store 
and forward,” services require the digital transmission of images or video and include 
diagnostic services such as teledermatology and teleradiology (MedPAC, 2016b).  
Each modality of telemedicine offers distinctive opportunities for improvements 
in health care access, quality, and efficiency. Direct-to-consumer services may improve 
convenience and access to primary care, particularly given evidence that the average wait 
time for an in-person primary care visit is longer than three weeks (Hayhurst, 2017). Prior 
studies have found that per episode costs (including for follow-up visits) were lower for 
direct-to-consumer visits relative to in-person visits (Ashwood, Mehrotra, Cowling, & 
Uscher-Pines, 2017; Gordon, Adamson, & DeVries, 2017). However, there is mixed 
evidence on the effects of such services on total utilization and costs. Prior research has 
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found that direct-to-consumer telemedicine expanded access to services for patients who 
were previously unconnected with a health care provider or otherwise would not have 
had a visit which resulted in higher overall spending (Ashwood et al., 2017; Gordon et 
al., 2017; Uscher-Pines & Mehrotra, 2014). In contrast, other research has concluded that 
the services mostly substituted for in-person visits (Courneya, Palattao, & Gallagher, 
2013). Overall, patients have reported high rates of satisfaction with direct-to-consumer 
services (Martinez et al., 2018; Pearl, 2014).  
Real-time provider-initiated telemedicine services have the potential to expand 
access to specialty care as well, in both urban and rural areas (ASPE, 2016; MedPAC, 
2018; Mehrotra et al., 2017; Totten et al., 2016). Analyses of Medicaid and Medicare 
claims have found that real-time services have been used primarily for behavioral health 
care (Mehrotra et al., 2017). There is some evidence that these services supplement in-
person visits instead of supplanting them (Douglas et al., 2016; Gilman & Stensland, 
2013; Mehrotra et al., 2017; Neufeld & Doarn, 2015). Real-time services also have been 
used to improve access to physician consultations in nursing homes and reduce 
hospitalizations (Grabowski & O’Malley, 2014).  
The supply of telemedicine is influenced by insurers’ coverage determinations. 
For example, fee-for-service Medicare’s coverage of telemedicine under the Physician 
Fee Schedule is generally limited to underserved rural areas (MedPAC, 2016b, 2018). 
Medicare Advantage plans are required to cover the same telemedicine benefits as those 
covered by fee-for-service Medicare and may also cover supplemental telemedicine 
services, but this is subject to review by the Centers for Medicare and Medicaid Services 
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(CMS) (MedPAC, 2016a). The Bipartisan Budget Act of 2018 expanded coverage of 
telehealth services for all Medicare beneficiaries. Geographic restrictions for fee-for-
service Medicare enrollees will be removed in 2019 for telestroke and dialysis services 
(MedPAC, 2016b). Starting in 2020, Medicare Advantage plans may cover in their basic 
benefit package telemedicine services beyond those covered by traditional fee-for-service 
Medicare plans, although these services have not yet been fully defined.  
Nearly all state Medicaid programs cover some telemedicine services, although 
plans vary with respect to which providers may bill for telemedicine visits (MedPAC, 
2018). While commercial plans also vary in their telemedicine coverage, evidence from a 
survey of health plans has shown that plans commonly provide direct-to-consumer 
services (MedPAC, 2018) (MedPAC, 2018). In addition, state “parity” policies that 
require private insurers to reimburse providers for telemedicine services at the same 
amounts as in-person services are associated with hospitals’ adoption of telemedicine and 
with outpatient telemedicine use among commercial enrollees (Adler-Milstein, Kvedar, 
& Bates, 2014; Harvey, Valenta, Simpson, Lyles, & McElligott, 2019). 
Prior research has described rates of telemedicine use among beneficiaries of 
specific public and private payers, focusing on specific years, types of telemedicine 
(direct-to-consumer, real-time, or asynchronous), and payer populations (Medicaid, 
Medicare, or commercial) (Ashwood et al., 2017; Douglas et al., 2016; GAO, 2017; 
Gilman & Stensland, 2013; Harvey et al., 2019; MedPAC, 2018; Mehrotra et al., 2017; 
Neufeld & Doarn, 2015). Rates of telemedicine use at the population level—and how that 
use varies across payers, provider types, and geographic regions—is largely unknown, 
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however. Insights generated from population-level analyses can inform discussions 
regarding the potential unrealized benefits of telemedicine, such as improving access 
across different patient populations and medical needs. Moreover, such evidence can 
illustrate the extent to which private and public payers’ coverage policies may drive the 
provision and growth of telemedicine.  
In this article we describe the supply and use of telemedicine at a population level 
for Minnesota in the period 2010–15. Using the Minnesota All Payer Claims Database, 
which covers nearly 90 percent of insured Minnesotans, we analyzed telemedicine use at 
the population level and how the provision of telemedicine varied over time and across 
provider types, coverage types, and geographic regions.  
Minnesota serves as an instructive case study for investigating the supply of 
telemedicine. First, the state encompasses both large metropolitan areas and rural areas 
with varying unmet health care needs that may be addressed by telemedicine. Second, 
Minnesota has enacted policies during the past decade aimed at expanding the use of 
telemedicine. Notably, in 2006 Minnesota’s Medicaid program began covering real time 
videoconferencing telemedicine services for mental health care at parity with in-person 
service delivery ("Telemedicine for CSHCN: a state-by-state comparison of Medicaid 
reimbursement policies and title V activities ", 2005). By 2009 some commercial payers 
were also covering telemedicine services (Wilson, Trout, Rampa, & Stimpson, 2016). 
The Minnesota Telemedicine Act of 2015 mandated universal reimbursement parity for 
telemedicine and in-person services beginning in January 2016 for Medicaid beneficiaries 
and in January 2017 for commercial beneficiaries (MHA, 2015). While this legislation 
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was implemented after our study period, it reflects policy makers’ advocacy of 
telemedicine provision. 
 
2.3. Study Data and Methods  
 
Study Design and Sample  
We performed a descriptive, retrospective analysis of telemedicine use in 
Minnesota in the period 2010–15, including people of all ages and most sources of health 
insurance coverage. The primary unit of analysis was a clinical visit, defined as a set of 
services provided to an individual on the same dates by the same provider.  
 
Data Sources  
Our primary data for 2010–15 came from the Minnesota All Payer Claims 
Database. This state repository of health care claims data contains integrated medical 
claims, pharmacy claims, and plan enrollment information derived from medical 
providers’ billing records sent to insurance companies, plan administrators, and public 
payers (MDH, 2016). The database effectively represents the population of health care 
claims for approximately 89 percent of Minnesotans with health care coverage and 83 
percent of the overall state population. Along with information about health care use, the 
database includes other de-identified data: a unique patient identifier across payers; 
monthly health plan enrollment status; patients’ demographic information, ZIP code of 
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residence, and diagnosis and procedure codes; and the performing provider’s National 
Provider Identifier.  
We augmented the information in the Minnesota All Payer Claims Database with 
administrative data from several sources. We obtained information on providers’ 
credentials and specialty from the National Plan and Provider Enumeration System and 
the Centers for Medicare and Medicaid Services Base Provider Enrollment files, which 
we linked to the database using providers’ National Provider Identifiers (CMS, 2018a). 
We linked patients’ ZIP codes to rural-urban commuting area codes, which classify ZIP 
codes into metropolitan, micropolitan, small town, and rural areas ("RUCA Data", 2005). 
For the supplemental analyses, we linked the information on telemedicine use from the 
database to several other provider-, ZIP code-, and county-level data sets, which we 
describe in the online appendix.  
 
Study Measures  
We investigated patterns of telemedicine across three categories of visits: direct-
to-consumer consultations, real-time provider-initiated consultations, and asynchronous 
provider-initiated consultations. We describe our methods for identifying telemedicine 
services in the appendix. Asynchronous services accounted for less than 2 percent per 
year of the overall telemedicine provision in our data. While we included these services 
in our analyses of overall rates of telemedicine use and volume of services, we excluded 
them from all other analyses.  
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The main descriptive variables included patients’ source of health insurance 
(coverage type), patients’ residence in a metropolitan or nonmetropolitan area, provider 
type, and physician specialty. We categorized patients as having coverage from Medicare 
only, Medicaid and other state public programs such as MinnesotaCare (here, collectively 
called Medicaid), Medicare and Medicaid (dual eligibility), or a commercial plan based 
on their source of coverage at the time of their visit. As described above, Medicare 
Advantage plans—as well as Medicare Cost Plans, another type of private Medicare 
health plan in Minnesota—could offer telemedicine services outside of the fee-for-service 
Medicare benefit during our study period. However, across all Medicare Advantage and 
Medicare Cost Plans in Minnesota in 2015, only one insurer reported offering 
telemedicine coverage outside of the fee-for-service Medicare benefit, and that insurer 
covered direct-to-consumer services ("Health care choices for Minnesotans on Medicare, 
2015 edition ", 2015). Given the similarity of telemedicine coverage across fee-for-
service and private Medicare plans during our study period, we combined all Medicare 
patients into a single category.  
We categorized providers delivering telemedicine services as nurse practitioners, 
physician assistants, psychologists, physicians, and other providers (for example, nurses, 
dietitians, and social workers). Among physicians, we considered the following 
specialties that represented the highest-volume suppliers of telemedicine in the data: 
addiction medicine, family medicine, internal medicine, nephrology, obstetrics and 
gynecology, psychiatry, and other specialties (such as dermatology, cardiology, and 
infectious diseases). We consolidated patient rurality categories based on patient 
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residences’ rural-urban commuting area classification into two groups: metropolitan and 
nonmetropolitan, which includes micropolitan, small town, and rural.  
 
2.4. Study Analyses  
 
First, we estimated rates of telemedicine use per 10,000 enrollees by coverage type in 
2010–15, including enrollees in the denominator if they had any professional service 
claims during the year. Next, we calculated the overall volume of telemedicine visits in 
the period by coverage and visit type.  
To examine the types of providers delivering telemedicine services, we calculated 
the percentage of visits delivered by each provider type in 2015. We further examined 
provider specialty by calculating the percentage of telemedicine visits by each specialty. 
We also described the distribution of coverage type, provider type, and physician 
specialties for direct-to-consumer services compared to that for real-time provider-
initiated services. Finally, we compared the sources of coverage, use of direct-to-
consumer versus real-time telemedicine services, and provider types and physician 
specialties supplying telemedicine services in metropolitan versus nonmetropolitan areas.  
In supplemental analyses we compared the characteristics of providers who 
delivered telemedicine services with those of providers who did not. We also compared 
clinic-level characteristics, including size and experience with telemedicine technologies, 
between these two categories of providers.  
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2.5. Limitations  
 
We acknowledge a number of study limitations. First, our data set might not have 
captured all telemedicine visits. Because using Current Procedural Terminology codes to 
capture telemedicine visits is a relatively new practice, there are likely inconsistencies in 
billing that lead to the underreporting of telemedicine services. We could not, therefore, 
distinguish between changes in billing practices for telemedicine services over time from 
real increases in telemedicine use. We describe this limitation in more detail in the 
appendix. 
Second, there are some general limitations to the Minnesota All Payer Claims 
Database. It does not collect data from limited-benefit plans (for example, dental plans 
and those covering accidents only); from federal programs such as Veterans Affairs, the 
Indian Health Service, and TRICARE; and from uninsured patients who sought care.  
Third, our study focused on telemedicine provision only in Minnesota, which has 
a unique health care policy landscape and is a rapid adopter of innovations in health care 
technology and delivery. For instance, Minnesota is one of only eight states that accept a 
telemedicine license from physicians located in other states (Thomas & Capistrant, 
2015). Therefore, these results might not be generalizable to all states. 
 
2.6. Study Results  
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The rate of telemedicine use in Minnesota increased rapidly, from 26 users per 
10,000 enrollees in 2010 to 113 users per 10,000 enrollees in 2015 across all coverage 
types (Figure 2-1). Growth was highest among people with commercial insurance, 
increasing from 10 to 171 users per 10,000 enrollees over the study period. People dually 
eligible for Medicare and Medicaid exhibited rates of telemedicine use that were 
comparable to those of commercial enrollees, with enrollees in Medicaid only and 
Medicare only (fee-for-service Medicare and Medicare Advantage combined) exhibiting 
lower rates of use.  
The number of telemedicine visits in Minnesota increased from 11,113 in 2010 to 
86,238 visits in 2015, representing growth of over 600 percent (Appendix Exhibit 2-1). 
The bulk of this increase was accounted for by increases in telemedicine use among 
commercial enrollees with direct-to-consumer visits. These visit volumes increased from 
2,242 visits in 2010 to 51,955 visits in 2015 (Appendix Exhibit 2-2). The volume of 
Medicaid and Medicare telemedicine visits also grew rapidly over this period, but to a 
lesser extent than that of commercial telemedicine visits (over 400 percent and 200 
percent, respectively). Despite this growth, only 0.7 percent of patients used any 
telemedicine during the study period.  
 
Provision of Telemedicine In Minnesota 
In 2015, nurse practitioners delivered 46 percent of telemedicine services, 
followed by physicians (35 percent), other provider types (10 percent), and physician 
assistants (6 percent) (Figure 2-2). Among physician specialties, psychiatry accounted for 
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the majority of telemedicine visits (52 percent), followed by family medicine (21 
percent), other physician specialties (9 percent), and nephrology (6 percent).  
 
Types of Telemedicine Visits in Minnesota  
Next, we examined the types of telemedicine services provided in 2015 and compared the 
distributions of coverage type, provider type, and physician specialty (for the subset of 
services delivered by physicians) for direct-to-consumer and real-time provider-initiated 
telemedicine visits. Ninety-five percent of direct-to-consumer services were supplied to 
commercial enrollees (Figure 2-3), while the majority of real-time services were supplied 
to public insurance enrollees (Medicaid, Medicare, and dually eligible for Medicaid and 
Medicare). 
A large majority of direct-to-consumer services were provided by nurse 
practitioners and physician assistants. In contrast, physicians provided a large majority of 
real-time provider-initiated telemedicine services. In the subset of physician-provided 
telemedicine visits, family medicine physicians provided the largest share of direct-to-
consumer services, while a majority of real-time provider-initiated telemedicine visits 
were provided by psychiatrists.  
 
Use of Telemedicine in Metropolitan Versus Nonmetropolitan Areas  
Seventy-nine percent of telemedicine visits in metropolitan areas were for the 
commercially insured (Figure 2-4). However, in nonmetropolitan areas a larger 
proportion of visits was provided to patients with Medicaid, Medicare, or both. To 
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determine whether this finding was due to the distribution of coverage types in 
metropolitan and nonmetropolitan areas, we calculated the rates of telemedicine use as a 
percentage of all enrollees by coverage type in nonmetropolitan areas compared to 
metropolitan areas. Rates of telemedicine use were highest in nonmetropolitan areas 
among people with both Medicaid and Medicare, followed by commercial, Medicaid, and 
Medicare enrollees (Appendix Exhibit 2-3). 
In metropolitan areas, rates of telemedicine use were highest for commercial 
enrollees. Unsurprisingly, relatively fewer Medicare beneficiaries used telemedicine in 
metropolitan areas, given Medicare’s limited reimbursement policy. In metropolitan areas 
over 70 percent of telemedicine visits were direct-to-consumer visits (Figure 2-4). In 
nonmetropolitan areas a large majority of visits were provider-initiated real-time visits. 
To determine whether these differences between metropolitan and nonmetropolitan areas 
could be attributed to patients’ characteristics, we controlled for patients’ age, sex, and 
coverage type in an adjusted analysis. The relationship between telemedicine visit type 
and rurality of residence remained robust (Appendix Exhibit 2-5).  
Most telemedicine visits in metropolitan areas were provided by nurse 
practitioners or physician assistants, while most visits in nonmetropolitan areas were 
provided by physicians (Figure 2-4). Finally, the majority of physicians who provided 
telemedicine services in metropolitan and nonmetropolitan areas were psychiatrists 
(Appendix Exhibit 2-4). 
 
Supplemental Provider Analysis  
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In our supplemental analyses to further examine provider attributes associated 
with telemedicine provision, we first linked providers from the Minnesota All Payer 
Claims Database with data from the Minnesota Statewide Quality Reporting and 
Measurement System, which we discuss in more detail in the “Supplemental Data 
Sources and Analyses” section of the appendix.  
Compared to the providers in this linked subset who did not deliver at least one 
telemedicine service in 2015, providers who did deliver telemedicine had a higher 
proportion who were affiliated with a Medicaid accountable care organization (ACO), 
were physicians instead of other provider types), worked in nonmetropolitan areas, and 
belonged to smaller medical groups (Appendix Exhibit 2-6). Additionally, we found that 
the average number of telemedicine services provided per year among all telemedicine 
providers was 29.3, but the median services provided per year were only 4.0—which 
implied a positively skewed distribution, with a few providers accounting for the vast 
majority of visits. Among providers who did not report supplying telemedicine, 64.4 
percent worked in a clinic with telemedicine capabilities (Appendix Exhibit 2-7). The 
most frequently cited barriers to telemedicine use by providers who did not supply 
telemedicine were the cost of providing telemedicine services (including equipment and 
staff costs), lack of reimbursement from payers for telemedicine, and insufficient internet 
bandwidth. 
 
2.7. Discussion  
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In the period 2010–15 telemedicine visit volumes grew rapidly among 
Minnesota’s insured population. We attributed this growth primarily to direct-to-
consumer visits among the commercial enrollee population, but provision of real-time 
provider-initiated services also increased significantly during this period. However, only 
a small minority of the population used telemedicine during the study period. This pattern 
of high growth but low overall use is aligned with national-level evidence from Medicare, 
Medicaid, and private payers (MedPAC, 2016b, 2018; MHA, 2015).  
Our analyses also revealed geographic variation with respect to the types of 
telemedicine services delivered and the coverage types of patients. In metropolitan areas 
most telemedicine services were patient-initiated direct-to-consumer services sought by 
commercial enrollees. In contrast, in nonmetropolitan areas the majority of telemedicine 
visits were provider-initiated real-time services provided by physicians and received 
disproportionately by patients enrolled in public programs—findings also consistent with 
existing evidence (MedPAC, 2018). These results suggest that in nonmetropolitan areas, 
telemedicine may have expanded access to specialty care. In metropolitan areas, in 
contrast, telemedicine appears to be increasing the convenience and accessibility of 
primary care.  
The patterns of telemedicine use that we observed were likely related to the types 
of telemedicine covered by different payers rather than just differing clinical needs across 
patient populations. For example, during our study period, commercial plans increasingly 
covered direct-to-consumer services, while fee-for-service Medicare and Medicaid in 
Minnesota covered only real-time provider-initiated telemedicine (MDH, 2018; 
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MedPAC, 2018). Perhaps consequently, we found low use of direct-to-consumer 
telemedicine among Medicaid patients. Despite these patterns of use in the data, 
Medicaid enrollees could also benefit from expanded access to direct-to-consumer 
services. For example, lower-income people report difficulties taking time off work to 
attend doctor appointments and could benefit from the convenience of direct-to-consumer 
visits (Lewis C, 2017 ). Payment policies that provide different access to telemedicine 
services for different groups of patients could exacerbate existing disparities in access to 
care. Ideally, payers would cover telemedicine services whenever there are benefits of 
doing so in terms of higher quality, increased access to care, and lower costs. However, 
the mixed evidence on the effects of telemedicine adds uncertainty to such determinations 
(MedPAC, 2018).  
Our findings also imply that telemedicine services in Minnesota were delivered 
by a diverse set of providers, including nurse practitioners, physician assistants, and 
physicians. Among physician specialties, psychiatrists provided the majority of services. 
This finding is consistent with national-level evidence from Medicare that mental health 
care accounts for a large share of telemedicine visits (MedPAC, 2018). It is unclear 
whether the relatively low frequency of telemedicine provision by other specialties 
reflects a lack of clinical benefit or other factors. For example, we found that physicians 
who did not provide telemedicine cited lack of equipment, staffing costs, limited internet 
bandwidth, and reimbursement policies as barriers to telemedicine. In contrast, 
physicians who did provide telemedicine were more likely to be affiliated with 
Minnesota’s Medicaid ACOs.  
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Alternative payment models that require providers to take on financial risk, 
including ACOs, may foster innovative uses of telemedicine. Future work should 
examine the role of telemedicine within Medicare and Medicaid ACOs and whether 
policy changes to reduce barriers associated with telemedicine use, such as the telehealth 
waiver for Next Generation ACOs and reimbursement parity under the Minnesota 
Telemedicine Act, lead to higher rates of telemedicine provision (CMS, 2018b). In 
addition, the expansion of telemedicine coverage under Medicare Advantage through the 
Bipartisan Budget Act of 2018 may lead to novel uses of telemedicine that could serve as 
a testing ground for further expansions in fee-for-service Medicare. In particular, because 
Medicare Advantage plans receive a capitated payment from CMS and bonuses for 
higher quality rankings, they have financial incentives to adopt innovative uses of 
telemedicine if they improve quality performance or reduce costs (MedPAC, 2016a). 
Because of the differences in reimbursements for telemedicine between Medicare 
Advantage and fee-for-service Medicare plans, future studies could examine telemedicine 
use within these patient populations separately.  
Current evidence on the effects of telemedicine on access to and the quality and 
cost of care is mixed, including whether real-time and direct-to-consumer telemedicine 
visits substitute for in-person services. Using an all-payer claims database to conduct a 
population-level analysis, we found distinctive patterns of telemedicine use across patient 
populations. Effective uses of telemedicine likely vary across patients, depending on 
geographic region, health conditions, and socioeconomic status. Our results also imply 
that differences in use across patient groups were driven at least in part by coverage 
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policies and the types of providers supplying telemedicine, instead of reflecting where 
telemedicine could provide the greatest benefit. Providers, payers, and policymakers 
should continue to investigate innovative uses of telemedicine, with a focus on aligning 
telemedicine provision with patient needs. The resulting evidence could be used to 
inform payment policy and guide the ongoing diffusion of telemedicine into health care 
delivery. 
 
2.8. Conclusion  
 
We found rapid growth of telemedicine in Minnesota in the period 2010–15 but 
low overall rates of use across the population. In metropolitan areas the majority of 
telemedicine services were DTC visits that could have increased the convenience of 
primary care for patients with commercial insurance. In nonmetropolitan areas, 
telemedicine services were primarily real time provider-initiated services, which could 
have expanded access to specialty services among patients enrolled in public programs. 
Our results suggest that coverage policies and provider reimbursement are important 
factors in determining which patients receive telemedicine and which types of 
telemedicine are provided. 
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Figure 2-1. Number of telemedicine users per 10,000 enrollees in Minnesota, by coverage 
type, 2010-2015 
SOURCE Authors’ analysis of data from the MN APCD. Enrollees in the exhibit must 
have had at least one professional claim during the calendar year to be included in the 
numerator and denominator.  
 
Note: Exhibit published in Health Affairs. Yu, J., Mink, P. J., Huckfeldt, P. J., 
Gildemeister, S., & Abraham, J. M. (2018). Population-Level Estimates Of Telemedicine 
Service Provision Using An All-Payer Claims Database. Health Affairs, 37(12), 1931-
1939.  
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Figure 2-2. Distribution of telemedicine visits, by provider type and physician specialty, 
2015 
 
Source: Authors’ analysis of data from the MN APCD, NPPES and Medicare Base 
Enrollment File. Provider Type is given by the Medicare Base Enrollment File and 
Physician Specialty by the NPPES. Only Direct-to-Consumer (DTC) telemedicine visits 
and those initiated by providers in real time are included in this exhibit. 
 
Note: Exhibit published in Health Affairs. Yu, J., Mink, P. J., Huckfeldt, P. J., 
Gildemeister, S., & Abraham, J. M. (2018). Population-Level Estimates Of Telemedicine 
Service Provision Using An All-Payer Claims Database. Health Affairs, 37(12), 1931-
1939. 
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Figure 2-3. Distribution of telemedicine visit coverage types, provider types, and 
physician specialties, by direct-to-consumer (DTC) status, 2015 
 
Source: Authors analysis of data from the Minnesota All Payer Claims Database, the 
National Plan and Provider Enumeration System (NPPES), and the Medicare Base 
Provider Enrollment File. Provider type is given by the Medicare file and physician 
specialty by the NPPES. Only Direct-to-Consumer (DTC) telemedicine visits and those 
initiated by providers in real time are included in this exhibit.  
 
Note: Exhibit published in Health Affairs. Yu, J., Mink, P. J., Huckfeldt, P. J., 
Gildemeister, S., & Abraham, J. M. (2018). Population-Level Estimates Of Telemedicine 
Service Provision Using An All-Payer Claims Database. Health Affairs, 37(12), 1931-
1939. 
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Figure 2-4. Distribution of telemedicine coverage, visit, and provider types, by rurality, 
2015 
Source: Authors’ analysis of data from the Minnesota All Payer Claims Database, the 
rural-urban commuting area dating coding system, the National Plan and Provider 
Enumeration System (NPPES), and the Medicare Base Provider Enrollment File. Only 
Direct-to-Consumer (DTC) telemedicine visits and those initiated by providers in real 
time are included in this exhibit. 
 
Note: Exhibit published in Health Affairs. Yu, J., Mink, P. J., Huckfeldt, P. J., 
Gildemeister, S., & Abraham, J. M. (2018). Population-Level Estimates Of Telemedicine 
Service Provision Using An All-Payer Claims Database. Health Affairs, 37(12), 1931-
1939. 
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2.9. Appendix 
 
Overview 
In this appendix, we first described how we identified telemedicine visits and limitations 
of the data. Next, we showed the additional exhibits described in the main paper. We then 
described the data sources and approach used for the supplemental analyses, as well as 
the exhibits and supplemental analysis results. Finally, additional figures and tables 
discussing trends in telemedicine use not included in the original publication are shown 
in this appendix.  
 
Identifying Telemedicine Visits 
We identified each category of telemedicine used during clinical visits by using 
Current Procedural Terminology (CPT) codes or CPT modifier codes appearing on 
professional claim lines. Specifically, we defined DTC services as CPT codes 98969 and 
99444, which correspond to the procedure, online medical evaluation (BCBS, 2017). For 
real-time, provider-initiated consultations, we used the CPT modifier code “GT” to 
identify telemedicine visits. Additionally, we used CPT codes related to telemedicine 
consultations (G0425, G0426, G0427, G0406, G0407, G0408), telemedicine facility fees 
(Q3014), and telemedicine transmissions (T1014) to capture other real-time services 
(CMS, 2019). In order to avoid double counting telemedicine services where an 
originating facility fee was billed (CPT code Q3014), we counted telemedicine facility 
fees as telemedicine visits if they were the only telemedicine-related service billed for a 
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patient on a particular service date. We defined asynchronous provider-initiated 
consultations using CPT modifier code “GQ” (CMS, 2019). For the provider-level 
analysis, we defined a provider as having delivered a telemedicine service in a particular 
year if he or she billed as the attending provider of the service in that year. 
 
Data Limitations  
By using CPT codes and CPT code modifiers to identify to telemedicine visits, we 
may not be able to distinguish between improvements in billing practices for 
telemedicine services from actual increases in telemedicine use. For example, there is 
evidence that physicians providing telestroke services do not always bill Medicare for 
patient consultations (MedPAC, 2018)(3). These changes in billing may also occur 
differently across CPT codes. For instance, among commercial payers that reimburse for 
telemedicine, DTC services may be more accurately recorded because they are a separate 
health care service with a specific CPT code. In contrast, there may be more 
discrepancies or omissions of CPT modifiers in billing for real-time services because they 
require the use of a CPT modifier. Additionally, there is variation across commercial 
payers in the reimbursement of real-time services ("Beginner’s Guide to Telehealth 
Reimbursement in 2018," 2018).  
Despite these limitations, we found that commercial, traditional Medicare, 
Medicare Advantage, and Medicaid FFS plans submitting the highest volumes of claims 
in the MN APCD representing 92.9%, 88.7%, and 93.2% of commercial, Medicare, and 
Medicaid enrollees respectively, all submitted telemedicine claims during our study 
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period. This implies that most health plans reimbursed at least some providers' 
telemedicine services and submitted these data to the MN APCD. 
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Appendix Exhibit 2-1. Volume of Telemedicine Visits, by Coverage Type, 2010-2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
80,000
90,000
100,000
2010 2011 2012 2013 2014 2015
Commercial Dual Eligibles Medicaid Medicare Total
C
o
u
n
t 
o
f 
T
el
em
ed
ic
in
e 
V
is
it
s
SOURCE Authors’ analysis of data from the MN APCD. 
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Appendix Exhibit 2-2: Volume of Telemedicine Visits, by Visit Type 
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Appendix Exhibit 2-3: Telemedicine Use Rate by Rurality and Coverage Type 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
50
100
150
200
250
300
350
Metropolitan  Non-Metropolitan
N
u
m
b
er
 o
f 
T
el
em
ed
ic
in
e 
U
se
rs
 p
er
 1
0
,0
0
0
 
E
n
ro
ll
ee
s
Medicaid Medicare Commercial Dual Eligibles
SOURCE Authors’ analysis of data from the MN APCD, Rural-Urban Commuting Area 
Data. NOTES Enrollees must have had at least one professional claim during the calendar 
year to be included in the numerator and denominator. Only real-time provider-initiated and 
DTC telemedicine visits are included in this exhibit.  
 
33 
 
Appendix Exhibit 2-4: Physician Specialties by Rurality, 2015  
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Appendix Exhibit 2-5: Robustness of telemedicine type use by coverage and rurality 
(metropolitan versus non-metropolitan status), to patient characteristics 2015 
 
In the following table, the binary outcome variable is whether a telemedicine 
encounter is a real-time provider-initiated visit or a DTC service. It takes on the value of 
1 if an encounter is a real-time service, and 0 if it is a DTC service. The coefficients 
represent differences in proportions of patients that use real-time, provider-initiated 
services versus DTC services, in non-metropolitan versus metropolitan areas and by 
coverage type. We show the results for both models with and without patient controls.  
 
 
Rurality only 
Rurality and Patient 
Controls 
Rurality and 
Coverage Type 
Rurality, Coverage Type and 
Patient Controls 
 
Coef. SE Coef. SE Coef. SE Coef. SE 
Patient lives 
in a Non-
metropolitan 
area 0.524*** 0.003 0.438*** 0.003 0.260*** 0.001 0.244*** 0.003 
Coverage 
        
Commercial 
(Reference)         
Medicare     0.604*** 0.005 0.595*** 0.006 
Medicaid     0.669*** 0.003 0.642*** 0.003 
Dual     0.714*** 0.003 0.712*** 0.003 
Female   -0.166*** 0.003   -0.094*** 0.003 
Age Category         
0-18 
(Reference)         
19-24   -0.078*** 0.008   -0.062*** 0.007 
25-34   -0.189*** 0.006   -0.177*** 0.005 
35-44   -0.196*** 0.006   -0.168*** 0.005 
45-54   -0.154*** 0.006   -0.140*** 0.005 
55-64   -0.114*** 0.006   -0.122*** 0.005 
65+   0.160*** 0.006   -0.135*** 0.006 
Constant 0.235*** 0.002 0.494*** 0.006 0.098*** 0.001 0.305*** 0.005 
N 86210        
*p<0.05 **p<0.01 ***p<0.001   
 
 
 
SOURCE Authors’ analysis of data from the MN APCD, Rural-Urban Commuting Area Data. NOTES Only real-
time and telemedicine encounters are included in this sample. The dependent variable, whether a telemedicine 
encounter is a real-time service, takes on the value of 1 if an encounter is a real-time service, and 0 if it is a direct-
to-consumer (DTC) service. Linear probability models using OLS and robust standard errors were used to examine 
this relationship. Each model controls for a different set of encounter characteristics. 
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Supplemental Data Sources and Analyses 
For the supplemental, provider-level analysis of the characteristics of 
telemedicine providers, we linked providers from the MN APCD with the Minnesota 
Statewide Quality Reporting & Measurement System (SQRMS), which contains quality 
metrics, provider, clinic, and medical group data for all physician clinics in MN 
(Minnesota Department of Health, 2018a). Physicians, physician assistants, and advanced 
practice registered nurses registered with a physician clinic are represented in the 
SQRMS. Because only certain provider types are represented in the SQRMS data, we 
were only able to merge a subset of the providers in the MN APCD with those registered 
in the as part of a clinic. This limited our population of providers to 40.3% of the original 
sample. 
 We identified each provider’s gender, whether they worked in a rural area, 
whether they participated in a Medicaid Accountable Care Organization (ACO), and the 
broadband penetration in the county in which the provider practiced. In addition, we 
linked these data with information from the 2015 American Community Survey (ACS) to 
identify the socio-economic status of the ZIP codes where each provider worked. 
Specifically, we examined the percentage of individuals with a bachelor’s degree or 
higher in the ZIP code, the percentage of individuals who were privately insured, and the 
percentage of households living below the Federal Poverty Level (FPL) (United States 
Census Bureau, 2015). We identified ACO providers by using a roster of providers 
participating in a Medicaid ACO in 2015 maintained by the Minnesota Department of 
Human Services ("Integrated Health Partnership Provider Roster”, 2015). We obtained 
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county-level broadband data from the Minnesota Office of Broadband Development 
("Availability of Wireline Broadband Service by County", 2015). Finally, we included a 
measure of county level primary care access by merging in a variable representing the 
county-level average annual percent of Medicare enrollees having at least one ambulatory 
visit to a primary care physician (Dartmouth Institute for Health Policy and Clinical 
Practice, 2016).  
We then looked at differences in their clinics’ responses to a health IT survey 
collected by the Minnesota Office of Health Information Technology (OHIT) 
("Minnesota e-Health Assessments”, 2015). This survey, fielded from February 18 to 
March 17, 2015, required that all physician clinics registered with the MN SQRMS 
respond. Clinics were asked about their experience with health IT broadly, as well as 
their use of telemedicine and the types of barriers they encountered for telemedicine 
services.   
 
Supplemental Analyses Results  
 
We first summarized clinic and provider-level characteristics for telemedicine and 
non-telemedicine providers. Among the subset of physicians working in MN clinics that 
we were able to link to the MN SQRMS database, a higher proportion were affiliated with 
a Medicaid ACO, were female, and worked in non-metropolitan areas compared to their 
non-telemedicine provider counterparts (Appendix Exhibit 2-6). The average number of 
telemedicine services provided per year was 29.3 and the median was 4 among all 
telemedicine providers. We found that relatively fewer telemedicine providers worked in 
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a large medical group, and the average clinic FTE of providers was smaller for telemedicine 
providers compared to non-telemedicine providers. 
Among providers that worked in a clinic that responded to the 2015 OHIT survey 
about IT capabilities in the clinic, we found that 83.6 percent of telemedicine providers 
worked in a clinic where telemedicine services were supplied, compared to 64.4 percent of 
non-telemedicine providers (Appendix Exhibit 2-7). The most frequently cited barriers to 
telemedicine use for both telemedicine and non-telemedicine providers were the cost of 
providing telemedicine services including equipment and staff costs, and the lack of 
reimbursement from payers for telemedicine. However, the percentage of clinics citing 
these barriers were higher amongst non-telemedicine providers.  
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Appendix Exhibit 2-6: Clinic and Provider Characteristics for Telemedicine and Non-
Telemedicine Providers 2015 
  Frequency 
% of 
Providers 
who 
delivered 
telemedicine 
services 
Frequency 
% of 
Providers 
who didn’t 
deliver 
telemedicine 
services 
Affiliated with a Medicaid ACO  179 20.1 1850 13.7 
Worked in non-metropolitan 
area 
186 20.8 2295 17.0 
Provider gender, Female 566 63.4 7548 55.9 
% of Medicare enrollees having 
at least one ambulatory visit to a 
primary care physician during 
the year, ZIP code-level 
68.5 68.5 
% Privately insured individuals, 
ZIP code-level 
70.9 74.0 
% Individuals with a bachelor’s 
degree or higher, ZIP code-level 
36.6 37.7 
% of families living below the 
FPL, ZIP code-level 
9.6 9.8 
% of households with broadband 
coverage, county-level 
90.5 91.8 
5th percentile 1 -- 
25th percentile 1 -- 
50th percentile 4 -- 
75th percentile 15 -- 
95th percentile 620 -- 
Average Number of 
Telemedicine Services Provided 
29.3 
-- 
Works in a large medical group 
(FTE >100) 
545 61.1 8381 62.1 
Average clinic full-time 
equivalent (FTE) for providers 
428.4 809.9 
N 892 13502 
SOURCE Authors’ analysis of data from the MN APCD, the ACS, MN county-level broadband 
coverage, the Dartmouth Institute for Health Policy and Clinical Practice, MN SQRMS. NOTES The 
MN SQRMS data contains only a subset of physicians that may be linked to a clinic in MN 
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Appendix Exhibit 2-7: Clinic Telemedicine Use Among Telemedicine and Non-
Telemedicine Providers 2015 
  
Among Providers who 
delivered telemedicine 
services 
Among Providers 
who didn’t deliver 
telemedicine services 
  Frequency % Frequency % 
Clinic used any telemedicine during the 
year 
731 83.6 8112 64.4 
Barriers         
Cost  562 64.3 9577 76.0 
Insufficient bandwidth  130 14.9 4584 36.4 
Lack of reimbursement for telemedicine 289 33.1 7515 59.6 
Lack of staff support 99 11.3 1658 13.2 
Lack of staff expertise 107 12.2 2233 17.7 
No demand for telemedicine 106 12.1 2520 20.0 
N  874 12600 
SOURCE Authors’ analysis of data from the MN APCD, MN OHIT Survey, MN SQRMS.  
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Additional Exhibits Showing Telemedicine Trends in Minnesota 
 We found increases in the overall volume spending from medical plans on 
telemedicine services across all coverage types from 2010 to 2015 (Appendix Exhibit 2-
8), corresponding to the increase in the number of telemedicine users over this time 
period (Figure 2-1). As discussed in the paper, this increase was primarily driven by 
increases in telemedicine use among commercially insured enrollees.  
 Within these two visit type categories, we looked at the five most common 
diagnosis codes on the claim (Appendix Exhibit 2-9). We focused on the primary 
diagnosis position and only claims in the calendar year 2015. DTC visits were primarily 
supplied for non-emergent primary care conditions: acute sinusitis, urinary tract 
infections, abnormal glucose, conjunctivitis, and candidiasis of vulva and vagina. As 
described in the paper, these visits were primarily supplied by nurse practitioners and 
physician assistants. Real-time visits were primarily provided for diagnosis codes related 
to major depressive affective disorders, attention deficit disorders, end stage renal 
disease, anxiety, and obstructive sleep apnea. This finding aligns with the provider type 
analysis showing that most real-time telemedicine visits were delivered by psychiatrists 
and other physician specialists (Figure 2-3).  
 We also examined individual level characteristics and telemedicine use. Appendix 
Exhibit 2-10 shows that telemedicine users in 2015 are primarily female compared to 
non-telemedicine users (71.62% vs. 54.27%), less likely to live in rural ZIP codes (7.47% 
vs. 10.13%), and are more likely to be in the 25-34 age bracket (23.79 % vs. 12.00%) 
compared to other age categories. They are also less healthy than the overall non-
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telemedicine user group, with a higher percentage of individuals with 3 or more chronic 
conditions (13.31% vs. 24.51%), and a higher probability of being a persistent high cost 
user (12.90% vs. 8.10%). When examining these categories by telemedicine visit type, 
we found that provider-initiated real-time telemedicine users were relatively older 
compared to DTC telemedicine users. Over 21 percent of provider-initiated telemedicine 
users were 65 years or older compared to 2 percent of DTC telemedicine users. Provider-
initiated telemedicine users were also much more likely to live in rural areas (20.35% vs. 
2.84%), and a larger percentage of provider-initiated users had three or more chronic 
conditions compared to DTC users (76.53% vs. 17.80%).  
In addition to these patient level characteristics, we examined wireless broadband 
availability of all households in the county (at least 10Mbps download and 5 Mbps 
upload speeds), which may impact whether individuals in the region have access to 
telemedicine services. While the majority of rural households have broadband internet 
services, they still lag behind the provision and adoption of high-speed internet 
technologies compared to urban areas, and telemedicine will have continue larger 
requirements for high-quality and reliable broadband in order to transmit data and expand 
the types of telemedicine services that may be accessed (FCC, 2018; Stenberg, 2018). 
Additionally, fewer rural providers may have access to higher bandwidth and faster 
broadband services compared to their urban counterparts, due in large to the costs of 
broadband in rural areas (Kaushal, Patel, Darling, Samuels, & McClellan, 2015).  
We find similar rates of Medicare access to care and broadband availability between 
telemedicine and non-telemedicine users overall. However, DTC users tend to live in 
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counties with higher broadband availability for households compared to provider-
initiated users (91.48% vs. 77.68%). 
Appendix Exhibits 2-11 and 2-12 show the marginal effects and standard errors 
generated from the binary logistic regression for whether telemedicine use is associated 
with the patient and county-level covariates shown in Appendix Exhibit 2-10, focusing 
on year 2015. We separated out DTC and provider-initiated telemedicine users and ran 
two separate logit models, where the outcome variable takes on the value of one if 
someone is a DTC telemedicine user (or a provider-initiated telemedicine user), and zero 
otherwise. We find that living in a metropolitan ZIP code (relative to living in a 
nonmetropolitan ZIP code), being female, and having fewer chronic conditions are all 
positively and significantly associated with DTC telemedicine use (Appendix Exhibit 2-
11). We find different results for the association between provider-initiated telemedicine 
use and patient characteristics, such that living in a nonmetropolitan ZIP code (relative to 
living in a metropolitan ZIP code), having more chronic conditions are positively 
associated with telemedicine use, and being 35 years or older (relative to being 18 years 
or younger), are positively and significantly associated with telemedicine use (Appendix 
Exhibit 2-12).  
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Appendix Exhibit 2-8: Overall Volume of Medical Spending from Medical Plans on 
Telemedicine Services Across all Coverage Types, 2010 to 2015 
 
Note: Medical spending is the amount paid by the health plan for medical care and 
pharmacy care respectively, and excluding patient out-of-pocket payments and withhold 
amounts.  
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Appendix Exhibit 2-9. Top 5 Diagnoses Codes for Telemedicine Services, by 
Telemedicine Type, 2015 
 
 
 
 
 
  
 
 
Note: Other diagnosis categories outside of the top 5 most common 
conditions are not included in the exhibits above. Direct-to-consumer is 
abbreviated as DTC. 
 
 
 
 
 
Acute Sinusitis
36%
Urinary Tract 
Infection
26%
Abnormal Glucose
28%
Conjunctivitis
6% Candidiasis of vulva and vagina
4%
DTC Telemedicine Visits
Anxiety
18%
Attention Deficit
21%
End Stage Renal 
Disease
20%
Obstructive sleep 
apnea
16%
Major depressive affective disorder
25%
Provider-Initiated Telemedicine Services
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Note: Broadband availability is measured at 10 Mbps download and 5 Mbps upload 
speeds. Direct-to-consumer is abbreviated as DTC. 
 
 
 
 
 
 
 
Appendix Exhibit 2-10. Descriptive Statistics for Demographics, All telemedicine 
services, 2015 
Category 
Telemedicine 
Users 
DTC 
Telemedicine 
Users 
Provider-
initiated 
Telemed. 
Users 
Non- 
Telemed
. Users 
Rural, % 7.47 2.84 20.35 10.13 
Female, % 71.62 77.41 55.56 54.27 
Age, 0-18, % 10.40 9.05 14.37 25.09 
Age, 19-24, % 6.01 5.95 6.29 6.64 
Age, 25-34, % 23.79 27.23 14.29 12.00 
Age, 35-44, % 21.45 24.15 14.05 10.93 
Age, 45-54, % 17.88 18.91 14.87 12.68 
Age, 55-64, % 13.39 12.75 14.89 12.83 
Age, 65+, % 7.09 1.96 21.24 19.83 
Chronic conditions     
1 or fewer chronic 
conditions, % 53.40 
68.16 12.31 64.18 
2 chronic conditions, % 13.29 14.04 11.16 11.32 
3 or more chronic 
conditions, % 33.31 
17.80 76.53 24.51 
Probability of being a 
Persistent High Cost User, 
% 
12.90 6.48 30.75 8.10 
% of Households with 
broadband availability, 
county level 
87.83 91.48 77.68 86.73 
N 56,679 41,778 14,980 4,234,598 
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Appendix Exhibit 2-11. Association between DTC Telemedicine Use and Patient 
Characteristics, Marginal Effects, 2015 
Patient Characteristics Marginal 
Effects 
SE p-value 
Metropolitan 0.003 0.000 0.000 
Female 0.010 0.000 0.000 
Age, 0-18 Ref.   
Age, 19-24 0.005 0.000 0.000 
Age, 25-34 0.017 0.000 0.000 
Age, 35-44 0.016 0.000 0.000 
Age, 45-54 0.010 0.000 0.000 
Age, 55-64 0.005 0.000 0.000 
Age, 65+ -0.003 0.000 0.000 
Chronic conditions -0.001 0.000 0.000 
Probability of being a Persistent High Cost 
User, 1st quartile 
Ref.   
Probability of being a Persistent High Cost 
User, 2nd quartile 
0.001 0.000 0.000 
Probability of being a Persistent High Cost 
User, 3rd quartile 
0.003 0.000 0.000 
Probability of being a Persistent High Cost 
User, 4th quartile 
0.004 0.000 0.000 
% of Households with broadband availability, 
county level, 1st quartile 
Ref.   
% of Households with broadband availability, 
county level, 2nd quartile 
0.003 0.000 0.000 
% of Households with broadband availability, 
county level, 3rd quartile 
0.004 0.000 0.000 
% of Households with broadband availability, 
county level, 4th quartile 
0.002 0.000 0.000 
N 4,136,913 
Note: Broadband availability is measured at 10 Mbps download and 5 Mbps upload 
speeds. Direct-to-consumer is abbreviated as DTC. 
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Appendix Exhibit 2-12. Association between Provider-initiated Telemedicine Use and 
Patient Characteristics, Marginal Effects, 2015 
Patient Characteristics Marginal 
Effects 
SE p-value 
Metropolitan -0.004 0.000 0.000 
Female -0.000 0.000 0.000 
Age, 0-18 Ref.   
Age, 19-24 0.001 0.000 0.064 
Age, 25-34 0.001 0.000 0.000 
Age, 35-44 -0.001 0.000 0.000 
Age, 45-54 -0.004 0.000 0.000 
Age, 55-64 -0.005 0.000 0.000 
Age, 65+ -0.007 0.000 0.000 
Chronic conditions 0.001 0.000 0.000 
Probability of being a Persistent High Cost 
User, 1st quartile 
Ref.   
Probability of being a Persistent High Cost 
User, 2nd quartile 
0.001 0.000 0.000 
Probability of being a Persistent High Cost 
User, 3rd quartile 
0.003 0.000 0.000 
Probability of being a Persistent High Cost 
User, 4th quartile 
0.009 0.000 0.000 
% of Households with broadband availability, 
county level, 1st quartile 
Ref.   
% of Households with broadband availability, 
county level, 2nd quartile 
-0.002 0.000 0.000 
% of Households with broadband availability, 
county level, 3rd quartile 
-0.002 0.000 0.000 
% of Households with broadband availability, 
county level, 4th quartile 
-0.001 0.000 0.000 
N 4,136,913 
Note: Broadband availability is measured at 10 Mbps download and 5 Mbps upload 
speeds. 
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3. Chapter 2: Direct-to-Consumer Telemedicine and Health Care Utilization, 
Quality, and Spending Outcomes 
 
 
Jiani Yu, Pamela J. Mink, Jean M. Abraham, Peter J. Huckfeldt 
 
Prepared for submission to JAMA Internal Medicine 
 
3.1. Synopsis  
 
Importance: Telemedicine, the use of telecommunications technology to remotely 
diagnose and treat patients, has the potential to lower health care spending while 
improving access to care, particularly in underserved areas. However, evidence on the 
impact of telemedicine visits on follow-up health care use, quality of care, and total 
spending is inconclusive due to mixed results from cross-sectional studies. Understanding 
these relationships is particularly important for evaluating the potential for telemedicine 
to substitute for in-person care for specific diagnoses and treatments. 
 
Objective: To examine the association of direct-to-consumer (DTC) telemedicine 
medicine visits with follow-up health care use, quality of care, and spending relative to 
in-person visits. 
 
Design, Setting, and Participants. We conducted a differences-in-differences analysis that 
compared non-elderly female enrollees of commercial plans that initiated DTC 
telemedicine coverage in 2011 relative to health insurance plans without DTC 
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telemedicine coverage. We identified 30-day episodes of care either initiated by a DTC 
telemedicine visit or an in-person visit for the treatment of urinary tract infections (UTIs) 
using the Minnesota All Payer Claims Database, between 2009-2014. We conducted 
intent-to-treat analyses to measure the association of DTC telemedicine coverage with 
study outcomes and used instrumental variables methods to estimate the association of 
DTC telemedicine use with study outcomes. We also assessed whether DTC telemedicine 
coverage increased the number of UTI visits at the health plan level and alternatively 
whether DTC telemedicine substituted for DTC visits.  
 
Exposures: Health insurance coverage of DTC telemedicine 
 
Main Outcomes and Measures: Total number of services and standardized amounts paid 
by health insurers within a 30-day period including the initial visit. We also specifically 
examined the number of evaluation and management visits, laboratory tests, and any 
emergency department and inpatient visits. We separately examined the number of 
prescriptions filled and number of antibiotic prescriptions filled within the first week after 
the initial visit. 
 
Results: A total of 17,338 episodes of care for UTI were initiated by a DTC telemedicine 
visit during the study period.  The initiation of health insurance coverage for DTC 
telemedicine was associated with a 17 percentage point increase in telemedicine-initiated 
episodes of UTI care (95% CI: 8.20, 25.82 percentage points; P <0.001). Coverage of 
DTC telemedicine was associated with fewer total services in a 30-day episode of care (-
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0.13 total services; 95% CI: -0.20 to -0.05; P<.001), fewer antibiotics of concern 
prescriptions filled (-0.04; 95% CI: -0.08 to -0.002), and lower average spending per 
episode of care (-26.21; 95% CI: -43.67, -8.75; P=.004).  
 
In instrumental variables analyses, we found that episodes of care initiated by DTC 
telemedicine visits resulted in fewer total services (-0.74; 95% CI: -0.92, -0.56; P <.001), 
including fewer evaluation and management follow-up office visits (-0.25; 95% CI: -
0.36, -0.14; P <.001), and fewer antibiotics of concern prescriptions filled (-0.25; 95% 
CI: -0.45,-0.04; P = .018). Total spending was lower on average for DTC telemedicine-
initiated episodes of care (-154.06; 95% CI: -192.09,-116.03; P <.001). The initiation of 
coverage for DTC telemedicine was not associated with a statistically significant 
difference in the total number of UTI visits (0.078; 95% CI: -0.17, 0.33; P=.535).  
 
Conclusions and Relevance: In this study of commercially insured Minnesotans treated 
for UTIs, an initial DTC telemedicine visit for non-elderly females was associated with 
reductions in the overall number of services, prescriptions for antibiotics of concern, and 
total spending during a 30-day episode of care. These results suggest that for UTIs, DTC 
telemedicine services may be effective in reducing utilization of specific health care 
services and medical spending, while maintaining a comparable quality of care to in-
person services. 
 
 
3.2. Introduction 
51 
 
In recent years, broader coverage of telemedicine services by payers, along with 
large investments to develop telecommunications and telehealth technologies, have led to 
rapid growth in telemedicine provision, although the use of telemedicine services is still 
relatively low compared with the use of in-person services. (Lagasse, 2017; MedPAC, 
2016; Vogenberg & Santilli, 2018; Yu, Mink, Huckfeldt, Gildemeister, & Abraham, 
2018). In particular, much of the growth in telemedicine use has been concentrated within 
direct-to-consumer (DTC) telemedicine visits, defined as patient-initiated, online medical 
evaluations for low-acuity conditions delivered via a computer or mobile platform 
(BCBS, 2017; MedPAC, 2016; Poon, Schuur, & Mehrotra, 2018; Yu et al., 2018). Unlike 
other types of telemedicine visits, DTC visits are primarily provided by nurse 
practitioners and physician assistants rather than clinicians, and by a separate provider 
rather than the patient’s individual primary care provider (Mehrotra, Paone, Martich, 
Albert, & Shevchik, 2013; Uscher-Pines et al., 2016).  
 The expansion of DTC telemedicine coverage and utilization may impact total 
health care use for individual patients, as well as the quality of care received and total 
medical spending. On the one hand, DTC telemedicine visits could decrease unnecessary 
use if they are effective at resolving patients’ clinical issues (Gordon, Adamson, & 
DeVries, 2017). DTC telemedicine visits may also improve individuals’ quality of care if 
they promote the use of more explicit clinical practice guidelines, resulting in better 
adherence to guidelines for diagnosis and treatment (Courneya, Palattao, & Gallagher, 
2013; Gali, Faiman, & Romm, 2018). Additionally, DTC telemedicine providers may be 
constrained in the types of services they can provide to patients, and therefore 
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unnecessary services may be reduced in a virtual care setting (Hennig-Schmidt, Selten, & 
Wiesen, 2011; McGuire, 2000). Alternatively, DTC telemedicine may result in higher 
utilization, poorer quality of care, and higher medical spending if it diminishes the quality 
of communication between providers and patients, reduces continuity of care, and leads 
to misdiagnoses or lower treatment adherence (Bavafa, Hitt, & Terwiesch, 2018; DeJong, 
Santa, & Dudley, 2014). Thus, the overall impact of DTC telemedicine on follow-up 
quality outcomes is theoretically ambiguous and requires empirical investigation. 
Expanding DTC telemedicine coverage also has potential benefits and harms in 
terms of access to care and the overall volume of visits. DTC coverage expansions may 
lead to increased access to care for patients with previously unmet care needs. However, 
expansions could also result in an increased overall volume of visits (including in-person 
and telemedicine visits) without expansions in access if for instance, DTC telemedicine 
visits appeal to “worried-well” patients that overuse medical services (Ashwood, 
Mehrotra, Cowling, & Uscher-Pines, 2017; Bavafa et al., 2018; Wagner & Curran, 1984). 
While we did not examine whether individuals overused telemedicine, we investigated 
whether DTC expansions increased the number of visits for UTI overall.  
Previous studies have largely focused on the association between DTC 
telemedicine use and episode-specific utilization, quality, and spending outcomes. Most 
studies have found that DTC telemedicine users to have similar or lower rates of follow-
up visits than those with in-person office visits in two studies (Gordon et al., 2017; 
Uscher-Pines & Mehrotra, 2014), but one study found that DTC telemedicine visits were 
associated with higher rates of follow-up visits for acute respiratory infections (Shi et al., 
2018). It is also unclear whether DTC telemedicine providers provide a lower quality of 
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care compared to non-telemedicine providers. One recent study concluded that DTC 
telemedicine providers supplied more antibiotics and less guideline-concordant 
antibiotics for a pediatric population compared to in-person providers (Ray et al., 2019). 
However, other studies have found higher or similar rates of rates of appropriate 
prescribing behavior for DTC telemedicine visits (Mehrotra et al., 2013; Shi et al., 2018; 
Uscher-Pines & Mehrotra, 2014; Uscher-Pines et al., 2016).  
The literature is generally consistent in finding that DTC telemedicine visits are 
priced lower than in-person visits, and result in lower medical expenditures over an 
episode of care (Courneya et al., 2013; Gordon et al., 2017; Uscher-Pines & Mehrotra, 
2014).  However, there is mixed evidence about whether DTC coverage expansions 
increase overall spending over an entire enrollee population by increasing the overall 
number of patients with visits. One study showed that expanded coverage of DTC 
telemedicine contributed to an overall increase in utilization of health care services, but 
studies using self-reported survey data concluded that DTC telemedicine visits primarily 
replaced in-person visits (Ashwood et al., 2017; Courneya et al., 2013; Player, O’Bryan, 
Sederstrom, Pinckney, & Diaz, 2018).  
Prior research on DTC telemedicine have relied primarily on cross-sectional 
designs, comparing DTC telemedicine and non-telemedicine episodes directly. To the 
extent that there are unobserved patient characteristics related to both choice of DTC 
telemedicine versus in-person visits and follow-on health care use and other outcomes, 
estimates from such studies may be biased, and may overestimate the capacity for DTC 
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telemedicine to improve patient outcomes. Additionally, most studies are limited to one 
insurer or employer, therefore limiting their generalizability.   
This study builds upon existing literature by comparing episodes of care within 
commercial insurers in Minnesota that began covering DTC telemedicine in the last 
quarter of 2010 relative to episodes of care within insurers that did not. Using a quasi-
experimental approach and the Minnesota All Payer Claims Database (MN APCD), we 
investigate how initiating an episode of care for a diagnosis of UTI with a DTC 
telemedicine visit influences utilization of follow-up care, spending, and quality. 
Additionally, we examined the substitution of DTC telemedicine for in-person care for 
UTI visits.  
 
3.3. Methods 
 
Research Setting 
Starting in the last quarter of 2010, multiple large commercial insurers in 
Minnesota introduced coverage for DTC telemedicine services, while others did not. We 
compared changes in health care use, quality of care, and spending between 2009 and 
2014, among individuals enrolled within insurers that expanded coverage of DTC 
telemedicine services relative to those enrolled within insurers that did not.  
 
Data 
We used 2009-2014 health care claims data from the MN APCD, a state 
repository of de-identified, medical claims, pharmacy claims, and plan enrollment data 
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across commercial and public payers in Minnesota.  Claims captured in the MN APCD 
for the study years represent approximately 89% of Minnesotans with health care 
coverage (MDH, 2016). We merged monthly medical enrollment data with medical 
utilization data, which contains the plan paid amounts and the number of unique services, 
which we linked with Berenson-Eggers Type of Service (BETOS) codes. This data also 
includes pharmacy utilization data, which contains the number of prescriptions filled, 
paid amounts for prescriptions, and National Drug Code (NDC) data (CMS). We 
supplement the MN APCD with other datasets to control for other demographic and 
health-related variables: 1) Rural-Urban Commuting Area (RUCA) codes ("RUCA 
Data”, 2005); 2) 2011-2014 5-year American Community Survey datasets (United States 
Census Bureau, 2014); 3) Dartmouth Atlas (Dartmouth Institute for Health Policy and 
Clinical Practice, 2016); 4) 2016 HEDIS Antibiotics of Concern drug list (HEDIS, 2017). 
 
Study Population 
We restricted attention to commercially insured individuals enrolled within 
insurers that adopted DTC telemedicine coverage and within insurers that did not. The 
commercial plan population includes individuals enrolled in employer-sponsored 
insurance plans (self-insured and fully-insured) and in plans on the individual health 
insurance market.  
We focused on UTIs, a highly prevalent primary care condition that has a 
substantial impact on health spending. Annually, 7 million office visits and 1 million ED 
visits are made for diagnosing and treating UTIs in the United States, corresponding to 
roughly $1.6 billion (Simmering, Tang, Cavanaugh, Polgreen, & Polgreen, 2017).  UTIs 
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also comprise a large proportion of DTC telemedicine visits, as diagnoses related to UTIs 
made up 19.2% of all diagnoses for health care services within the study data. Because 
the occurrence of UTIs is very rare among males under age 50, we restricted our sample 
to females only (Tan & Chlebicki, 2016).  
In an additional analysis, we were interested in whether DTC telemedicine 
differentially impacted episodes of care for more complicated UTIs, and therefore we 
subset the sample to adult females over the age of 50, given the higher risk of 
complicated UTIs among older individuals (Rowe & Juthani-Mehta, 2013; Sabih & 
Leslie, 2019). We also subset the sample into female patients with two or more diagnoses 
of UTI over a calendar year, and those with just one, in order to examine whether 
individuals with more familiarity and knowledge of treating UTIs may experience more 
favorable outcomes related to DTC telemedicine use (Hooton & Gupta, 2018). 
We identified in-person and DTC telemedicine visits among the insurers in our 
sample occurring between January 1, 2009 to December 31, 2014 with a primary 
diagnosis for UTI or dysuria (AFHSB, 2016) (Appendix Exhibit 3-1). We investigated all 
health care use occurring within the subsequent 30 days of the initial visit, and allowing 
for a 3-week period before new UTI-related episodes of care (Appendix Exhibit 3-2) 
(MacVane, Tuttle, & Nicolau, 2015). All other diagnoses within the episode of care must 
pertain to diagnoses of signs and symptoms involving the genitourinary system, 
symptoms involving the urinary system, and diseases of the urinary system, but may 
occur at any diagnosis position on the claim (Appendix Exhibit 3-1) (MacVane et al., 
2015). We defined DTC telemedicine encounters as claims with a CPT codes or 98969 or 
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99444, which correspond to a patient-initiated online medical evaluation procedure 
(BCBS, 2017; Excellus, 2006; Glabman, 2010). 
 
Outcome Variables 
Our study outcomes included measures of health care utilization, health care 
quality, and spending. The primary utilization outcome was the total number of unique 
services, including the initial encounter during the 30-day episode of care. We then 
examined the number of UTI follow-up services in the episode, subset into the following 
mutually exclusive categories: new and established evaluation and management visits, 
relevant lab tests – urinalysis and bacterial urine cultures, and all other lab tests based on 
BETOS categories (CMS). We also examined whether there were any inpatient and 
emergency department (ED) visits during the episode, and the total number of 
prescriptions filled.  
The primary quality outcome was the number of guideline-concordant, for first 
line antibiotics filled during the first week of an episode of care (Colgan & Williams, 
2011; Zoorob, Sidani, Fremont, & Kihlberg, 2012). We also examined the number of 
antibiotics of concern filled during the episode of care, as given by the 2016 HEDIS 
Antibiotics of Concern drug list, which are antibiotics considered to have broad-spectrum 
activity (HEDIS, 2017). 
The main spending outcome measure was the total price-standardized medical 
plan paid amount (excluding out-of-pocket payments) over a 30-day episode of care. We 
discuss how we derived standardized payment amounts in the Appendix. Finally, for the 
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population-level analysis of UTI visits, we calculated the rates of overall in-person and 
DTC telemedicine visits for UTIs per 10,000 health plan enrollees.  
 
Control Variables 
We controlled for several patient-level characteristics, including age (19-24; 25-
34; 35-44; 45-54; 55-64), comorbidities (congestive heart failure, depression, bipolar 
disorder, diabetes, hypertension, ischemic heart disease, persistent asthma, rheumatoid 
arthritis, schizophrenia, chronic obstructive pulmonary disorder, chronic renal failure, 
low back pain), the probability of being a persistent high cost user (whether someone is 
likely to be in the top quintile in terms of costs among the population for two consecutive 
years), and metropolitan status of residence (metropolitan and micropolitan vs. small 
town and rural) ("The Johns Hopkins ACG® System Excerpt”, 2014). While the MN 
APCD does not contain patient-level income data, we proxied for socioeconomic status 
using ACS estimates for the percentage of individuals with a bachelor’s degree or higher 
in the ZIP code, the percentage of individuals who were privately insured, and the 
percentage of households living below the Federal Poverty Level (FPL) (US Census 
Bureau). We also included an annual measure of county level primary care access by 
using the county-level average annual percent of Medicare enrollees having at least one 
ambulatory visit to a primary care physician (Dartmouth Institute for Health Policy and 
Clinical Practice, 2016).  
 
Statistical Analysis 
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First, we performed descriptive analyses to compare the characteristics of 
enrollees with UTI episodes in health plans adopting DTC telemedicine to enrollees in 
health plans not adopting DTC telemedicine, in 2009-2010 (pre-period) and 2011-2014 
(post-period).  
Next, we conducted an intention-to-treat difference-in-differences (DID) analysis. 
UTI episodes of care for individuals enrolled in a health plan product within insurers 
offering DTC telemedicine coverage comprised the treatment group, while episodes of 
care for individuals enrolled in a health plan product within insurers that did not change 
their DTC telemedicine coverage were allocated to the comparison group (Appendix 
Exhibit 3-3). This analysis captures the association of study outcomes with plans’ 
coverage of DTC telemedicine without distinguishing between DTC telemedicine users 
and non-users. We estimated linear regression models where the explanatory variables 
included indicator variables for being in the treatment group in the post period, as well as 
the year the UTI occurred and the health insurance plan. The explanatory variable of 
interest is the interaction of being covered by an insurer offering DTC telemedicine 
coverage and the period following DTC coverage. The decision to cover telemedicine 
may be determined at the insurer level, but because individuals are enrolled within 
specific health plan products (e.g. preferred provider organization (PPO) plan, point-of-
service (POS) plan) with varying cost-sharing mechanisms, we clustered our analyses at 
the health plan product-insurer level. We adjusted for health insurer-plan product and 
year fixed effects, as well as patient and zip-level characteristics. 
In order to estimate the association of a DTC telemedicine visit with follow-up 
outcomes, we then estimated an instrumental variables (IV) approach. Since telemedicine 
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use is not randomly assigned in this study, estimates of the effect of DTC telemedicine 
may be biased because of selection bias and/or confounding.  For instance, individuals 
that decide to use telemedicine may differ from those that choose to use in-person care in 
ways related to our outcomes of interest. Previous studies have shown that individuals are 
very different in their preferences for virtual versus in-person services. DTC telemedicine 
users overall tend to be younger, healthier, and are more likely to be women than men 
(Courneya et al., 2013). We also found that among the commercially insured female 
enrollees in our study sample with a UTI episode of care, DTC telemedicine users were 
younger, healthier, and more likely to live in a metropolitan area (relative to a 
nonmetropolitan area) (Appendix Exhibit 3-4). These demographic characteristics are 
likely to be related to health outcomes and health spending. Our analyses used the 
expansion of coverage of DTC telemedicine services in MN among a subset of insurers in 
the last quarter of 2010, as an instrument to approximate random assignment of patient 
episodes to treatment and comparison health plan products.  
 The first stage of the IV was a DID analysis similar to the intent-to-treat 
described above, but the outcome was whether a UTI episode was initiated by a DTC 
telemedicine visit. In the second stage, we estimated the association between predicted 
telemedicine use and the outcomes of interest adjusting for control variables. The 
coefficient of interest indicates the local average treatment effect of DTC telemedicine 
use among enrollees within payers taking up DTC telemedicine. 
In addition to the main analysis, we stratified the model by age (50 years or over, 
less than 50 years), in order to determine whether individuals who were older and may 
have increased health risks, experienced relatively different outcomes related to DTC 
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telemedicine use compared to a younger sample. If DTC use leads to worse outcomes for 
higher risk populations, then this is an important finding to highlight. We also conducted 
additional analyses focusing on individuals who have recurring visits for UTI over a year 
period in order to determine whether experience with UTIs leads to relatively better DTC 
telemedicine outcomes (Appendix Exhibit 3-5). 
Finally, we examined the change in the total number of in-person and DTC 
telemedicine UTI evaluation and management visits as outcome measures, in order to 
determine if telemedicine visits for UTI replaced in-person visits after the coverage 
expansion of DTC telemedicine visits. Our empirical strategy and specification checks 
are described in more detail in the Appendix.   
 
3.4. Results  
From 2009 to 2014, there were 148,163 DTC telemedicine visits for UTI or 
dysuria covered by commercial insurers identified in the MN APCD – 17,338 initiated 
with a DTC telemedicine visit, and 130,825 initiated with an in-person visit. Individuals 
in the treatment and comparison groups were similar across patient and county-level 
characteristics. Those in the treatment group were slightly older (mean age, 40.7 vs 39.0 
years) in the pre-period, were more likely to live in a metropolitan area (75.3% vs 
70.8%), and had a higher probability of being a high cost user (9.5% vs 8.3%) (Table 3-
1). Treatment group enrollees also had fewer services in the pre-period over an episode of 
care relative to comparison group enrollees (mean services, 2.2 vs 2.3), and slightly 
higher standardized medical plan paid spending (mean spending 246.85 vs 242.84 
dollars) (Table 3-2). These treatment and comparison group episodes are relatively more 
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similar than telemedicine and non-telemedicine episodes, giving us some confidence that 
selection bias is reduced in our IV approach (Appendix Exhibit 3-4). We show the 
association between DTC telemedicine initiation and each outcome of interest in 
Appendix Exhibit 3-6. 
 
Intention-to-Treat Results 
Among individuals enrolled in a plan from payers that expanded DTC coverage, 
the percentage of episodes of care initiated by a DTC telemedicine visit substantially 
increased to 27% within the treatment group, compared to episodes within the 
comparison group over the 2009 to 2014 period (Figure 1). In the intention-to-treat DID 
results, which represent the association of the expansion of DTC telemedicine coverage 
in the post period on episode-level outcomes, treatment group episodes in the post period 
had a relatively lower number of overall services (-0.13; 95% CI: -0.20,-0.05; P< .001), 
driven in part by a reduction in the number of established evaluation and management 
visits and lab tests (urinalysis, other), and a two percentage point lower probability of 
having an ED visit (-0.02; 95% CI: -0.02, -0.01; P< .001) (Table 3-2). There were no 
statistically significant differences in the number of procedures, new evaluation and 
management visits, inpatient visits, prescriptions filled due to expansion of DTC 
telemedicine coverage. There were fewer antibiotics of concern prescriptions filled (-
0.04; 95% CI: -0.05 to -0.03; P= .039), but no differences in appropriate antibiotics 
prescriptions filled within the first week of the episode of care (Table 3-2). Treatment 
episodes in the post period also saw a decrease in standardized medical spending relative 
to the comparison episodes (-26.21; 95% CI: -43.67,-8.75; P= .004) (Table 3-2).  
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Instrumental Variable Results 
In the instrumental variable DID results, the first stage coefficients show that 
DTC telemedicine initiation increased by 17 percentage points in the post period within 
health plans that covered DTC telemedicine (F = 14.91) (Table 3-2). The second stage 
coefficients show that DTC telemedicine visits were associated with fewer medical 
services over the entire episode (-0.74 services; 95% CI: -0.92,-0.56; P< .001). The 
overall reduction was driven by fewer established E&M visits (-0.249; 95% CI: -0.361,-
0.137; P< .001), urinalysis tests (-0.252; 95% CI: -0.338, -0.166, P< .001), and ED visits 
(-0.10; 95% CI: -0.17, -0.02; P= .015). DTC telemedicine initiation was also associated 
with fewer antibiotics of concern filled (-0.25; 95% CI: -0.45, -0.04; P= .018). For the 
spending outcomes, DTC telemedicine initiation was associated with a decrease in 
standardized medical spending relative to in-person initiated episodes (-$154.06; 95% CI: 
-192.00,-115.29; P< .001) (Table 3-2). In the model stratified by age, individuals aged 50 
or over saw relatively higher reductions in the total number of services and medical 
spending compared to the under 50 group (Table 3-3). However, the lower probability of 
having any ED visit for DTC telemedicine-initiated episodes and the number of urinalysis 
tests are no longer statistically significant (Table 3-3). 
 
The Substitutability of DTC Telemedicine Services  
There was no statistically significant change in total rate of UTI visits in health 
insurance plan products introducing DTC telemedicine coverage relative to the 
comparison products. In the post-period, there were 19 more UTI-related, initial DTC 
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telemedicine evaluation and management visits per 10,000 enrollees (95% CI, 0.03, 0.34; 
P = 0.018) among plan products in payers that expanded telemedicine coverage, relative 
to those within payers that did not increase coverage for telemedicine services (Table 3-
5). This increase in the magnitude of telemedicine visits is accompanied by a decline, 
although statistically non-significant, of initial in-person visits for UTI, suggesting that 
DTC telemedicine visits for UTI in part replaced in-person visits during the study period 
(Table 3-5).  
 
3.5. Discussion 
 
We compared changes in health care use, quality, and spending for UTIs between 
episodes of care for individuals enrolled in a health insurance plan product within an 
insurer introducing coverage for DTC telemedicine, relative to episodes for enrollees 
enrolled in a plan product within the insurer comparison group. We found that DTC 
telemedicine coverage and use were associated with reductions in overall services, 
similar to the conclusion drawn in another study looking at DTC telemedicine, which 
concluded that only six percent of DTC telemedicine visits resulted in follow-up visits, 
compared to 13 percent of office visits (Uscher-Pines & Mehrotra, 2014). Our findings 
are different from a study focused on acute respiratory infections, which found a higher 
level of follow-up visits in DTC telemedicine initiated episodes (Shi et al., 2018). A 
separate study did not find any differences in follow-up care between in-person and DTC 
telemedicine episodes but did find however, similar to our results, that episodes initiated 
with a DTC visit had fewer ED visits and lab rates (Gordon et al., 2017).  
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In addition to lower episode-level utilization, we found lower standardized 
medical spending by about $154 for DTC telemedicine initiated episodes, which falls 
between the range of spending amount decreases concluded in other DTC telemedicine 
studies – $128, based on a study focused on lower genitourinary system infections, and 
$162, based on a study of commercial enrollees within on insurer (Courneya et al., 2013; 
Gordon et al., 2017).  
Our results present some initial evidence that DTC telemedicine services may 
result in lower utilization and spending for UTIs or similar primary care conditions where 
clinical guidelines for treatment are clearly outlined, within a commercially insured 
population. Our findings also suggest that patients with DTC telemedicine visits received 
comparable or better quality of care relative to in-person services for UTIs. We found 
reductions in harmful antibiotic prescribing, and no evidence that DTC telemedicine was 
associated with higher rates of ED or hospital admissions. We found some differences in 
the patterns of results for older UTI patients however. These patients are more likely to 
have additional comorbid conditions and more medically complex cases relative to 
younger UTI patients. We found an overall reduction in the number of services and 
medical spending among this older population, but we did not find that telemedicine 
initiated episodes of care lead to a lower probability of having an ED visit, nor fewer 
established office visits. 
Finally, we found that coverage of DTC telemedicine was not associated with a 
statistically significant increase in the total UTI visit rate at the population-level, 
suggesting that DTC telemedicine visits at least in part, substituted for in-person UTI 
visits over the study period. These findings support the conclusions from other studies 
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looking at whether telemedicine replaced in-person visits based on self-reported data 
(Courneya et al., 2013; Player et al., 2018). Our finding may be unique to conditions such 
as UTI where patients require immediate care, which may explain why these conclusions 
contrast with previous findings that concluded that for upper respiratory infections, the 
majority of DTC telemedicine visits represented new utilization rather than substitution 
of in-person visits (Ashwood et al., 2017). Our results are relevant for policies or payer-
level health plan benefit decisions that alter the coverage of DTC telemedicine services 
for individuals. For conditions where quality of care provided through DTC telemedicine 
is comparable to in-person care, more payers may consider covering DTC telemedicine 
as part of their benefit designs. Because we focused on one primary care condition – 
UTIs, more conditions must be examined in future work. 
The tradeoff to expanding DTC telemedicine coverage however, is that continuity 
of care may be reduced, and routine services such as preventive care services and 
wellness checks that typically occur during an in-person primary care consultation may 
not be provided to patients using telemedicine (Xu, 2002). Finally, although we don’t 
find an expansion in volume of services and access, we were only focusing on 
commercial patients – and the impact on access may be different for publicly insured 
patients or patients with lower socioeconomic status, who may have greater unmet needs 
for care. Policymakers may therefore also consider the potential of DTC telemedicine 
services to expand access to convenience care for non-commercially insured populations. 
For instance, the most widely cited barriers to receiving care for Medicaid beneficiaries 
with disabilities besides coverage restrictions, are transportation and long wait times (“ 
Health Care Experiences of Adults", 2017). Unlike retail clinics which are typically 
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located in metropolitan areas, DTC telemedicine has the potential to improve access in 
underserved areas (RAND, 2016). Finally, the expansion of DTC providers may also 
have positive spillover effects on uninsured patients, if these new services provide care at 
much lower out-of-pocket cost than in-person services.  
 
3.6. Limitations 
 
This study encompasses several limitations that lay out paths for future research. 
First, our study results are relevant to one prevalent, primary care condition – UTIs. 
Subsequent work may focus on a broader scope of primary care conditions that may be 
treated via DTC telemedicine. We were also limited in our patient population, as we 
focus only on non-elderly females. Second, these data only encompass health care claims 
for commercially insured Minnesotans. Therefore, telemedicine services that are paid 
entirely out-of-pocket by patients are not included in the analysis. Third, this analysis 
focuses on the early adopters of telemedicine services – both at the patient-level and at 
the payer-level. Patients that are the most likely to use telemedicine after it became 
available among certain payers, and payers that are most likely to adopt new innovations 
may be very different than those unlikely to engage in virtual care. Finally, there may be 
residual bias that our study design did not fully adjust for. For instance, if the 
composition of UTI patients in the treatment or control group changed differentially in an 
unobserved way, or if there was another coverage policy that changed at the same time as 
DTC coverage expansions for your DTC insurers, our results would be biased. 
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3.7. Conclusion  
 
Using a quasi-experimental empirical strategy, we found that DTC telemedicine 
coverage of and visits for UTIs were associated with reductions in follow-up services and 
medical spending, without diminishing quality of care. Additional work is needed to 
understand whether these patterns persist for other conditions, and for publicly insured 
and elderly populations, and other types of telemedicine visits. Given rapid advancements 
in consumer-facing telemedicine technologies and growth of new care delivery models, 
our findings warrant the need for future research to examine DTC use in commercial 
populations in other states, as well as the impact of DTC telemedicine use on continuity 
of care. 
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Figure 3-1. DTC Telemedicine-initiated episodes of care by treatment status 
All episodes of care for enrollees enrolled in a plan product belonging to a first mover 
direct-to-consumer (DTC) telemedicine payer are in the treatment group. All episodes of 
care for enrollees enrolled in a plan product belonging to a payer that did not cover DTC 
telemedicine services are in the comparison group. This analysis also contains only 
commercially-insured female patients enrolled in one of the treatment or comparison 
payer plans, with a urinary tract infection episode of care in the MN APCD, 2009-2014. 
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Table 3-1. Patient characteristics and study outcomes by DTC telemedicine coverage period and treatment status 
 Pre intervention  (2009-2010) Post intervention (2011-2014) 
Variable Treatment Comparison Treatment Comparison 
Individual Characteristics, mean (SD)     
Age 40.68 (13.90) 39.00 (13.69) 40.37 (13.85) 39.18 (13.99) 
Probability of Persistent High Cost 
User 
9.49 (14.20) 8.34 (13.23) 8.94 (14.06) 8.70 (13.80) 
Number of chronic conditions 1.62 (2.06) 1.26 (1.89) 1.61 (2.09) 1.30 (1.95) 
Primary care access in zip code 78.33 (8.28) 78.55 (7.62) 75.01 (8.30) 74.98 (8.77) 
Percent with bachelors degree or 
higher in zip code 
32.36 (14.76) 33.60 (14.95) 33.75 (15.02) 34.05 (14.95) 
Below federal poverty level in the past 
12 months in zip 
10.22 (6.91) 9.68 (6.36) 10.11 (6.74) 9.72 (6.21) 
Private coverage 78.46 (9.77) 79.17 (9.45) 78.57 (9.77) 79.11 (9.23) 
Lives in a metropolitan area, No. (%) 6,886 (75.29) 26,300 (70.81) 14,562 (74.14) 61,229 (74.46) 
Chronic conditions, No. (%)     
Bipolar disorder 83 (0.91) 345 (0.93) 187 (0.95) 751 (0.91) 
Congestive heart failure 130 (1.42) 580 (1.56) 355 (1.80) 1,489 (1.81) 
Chronic Obstructive Pulmonary 
Disorder 
39 (0.43) 149 (0.40) 77 (0.39) 258 (0.31) 
Chronic renal failure 57 (0.62) 208 (0.56) 130 (0.66) 440 (0.52) 
Depression 2,442 (26.63) 11,471 (30.82) 5,846 (29.70) 25,448 (30.90) 
Diabetes 497 (5.42) 2119 (5.69) 1118 (5.68) 4,514 (5.48) 
Hypertension 1,522 (16.60) 7,118 (19.12) 3,189 (16.20) 14,877 (18.06) 
Ischemic heart disease 63 (0.69) 234 (0.63) 94 (0.48) 424 (0.51) 
Persistent asthma 1,012 (11.04) 4,999 (13.43) 2,503 (12.71) 11,186 (13.58) 
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Rheumatoid arthritis 139 (1.52) 762 (2.05) 336 (1.71) 1,517 (1.84) 
Low back pain 1,435 (15.65) 6,786 (18.23) 3,283 (16.68) 15,358 (18.65) 
N  37,142 9,146 82,233 19,642 
Note: Direct-to-consumer is abbreviated as DTC in the table above. This analysis contains only commercially-insured female  
patients enrolled in one of the treatment or comparison payer plans, with a urinary tract infection episode of care in the MN  
APCD, 2009-2014. 
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Table 3-2. Intent-to-treat and instrumental variables analysis of DTC telemedicine-initiation on patient outcomes 
 Pre-period Outcomes 
Post-period 
Outcomes Intent-to-treat results Instrumental variable results 
 Mean (SD) Coefficient 95% CI p-value Coefficient 95% CI p-value 
Outcomes Treatment Comp. Treatment Comp.       
First Stage 
    
      
Probability of having a 
telemedicine-initiated 
episode 
0.002 
(0.049) 
0.000 
(0.010) 
0.208 
(0.406) 
0.006 
(0.078) 
0.170 
0.082 to 
0.258 
0.000  
  
Service Categories Mean (SD)       
Number of all services, total 
episode of care 
2.18 
(1.33) 
2.25 
(1.39) 
1.98 
(1.25) 
2.22 
(1.29) 
-0.126 
-0.198 to 
-0.054 
0.001 -0.740 
-0.920 to 
-0.560 
0.000 
Number of procedures, 
follow-up care 
0.02 
(0.14) 
0.02 
(0.15) 
0.01 
(0.13) 
0.01 
(0.13) 
0.000 
-0.004 to 
0.004 
0.945 0.001 
-0.020 to 
0.022 
0.945 
Number of new office visits, 
follow-up care 
0.04 
(0.19) 
0.03 
(0.18) 
0.04 
(0.19) 
0.04 
(0.20) 
0.001 
-0.004 to 
0.007 
0.629 0.008 
-0.024 to 
0.041 
0.620 
Number of established office 
visits, follow-up care 
0.34 
(0.54) 
0.36 
(0.55) 
0.28 
(0.51) 
0.37 
(0.54) 
-0.042 
-0.077 to 
-0.007 
0.018 -0.249 
-0.361 to 
-0.137 
0.000 
Number of other evaluation 
and management visits, 
follow-up care 
0.10 
(0.11) 
0.01 
(0.11) 
0.01 
(0.09) 
0.01 
(0.08) 
-0.000 
-0.004 to 
0.003 
0.841 -0.002 
-0.022 to 
0.018 
0.833 
Number of urinalysis tests, 
follow-up care 
0.31 
(0.54) 
0.31 
(0.54) 
0.27 
(0.51) 
0.32 
(0.54) 
-0.043 
-0.063 to 
-0.023 
0.000 -0.252 
-0.338 to 
-0.166 
0.000 
Number of bacterial culture 
tests, follow-up care 
0.24 
(0.50) 
0.26 
(0.53) 
0.19 
(0.44) 
0.24 
(0.49) 
-0.020 
-0.043 to 
0.003 
0.088 -0.116 
-0.236 to 
0.005 
0.060 
Number of all other tests, 
follow-up care 
0.13 
(0.38) 
0.16 
(0.44) 
0.10 
(0.34) 
0.15 
(0.42) 
-0.016 
-0.030 to 
-0.003 
0.019 -0.095 
-0.162 to 
-0.028 
0.005 
Any ED or Inpatient Care No. (%)       
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Any ED visits, follow-up 
care 
2863 
(7.69) 
472 (5.15) 
5,017 
(6.09) 
1,110 
(5.64) 
-0.020 
-0.024 to 
-0.008 
0.000 -0.095 
-0.171 to 
-0.019 
0.015 
Any inpatient visits, follow-
up care 
58 (0.16) 17 (0.19) 101 (0.12) 
36 
(0.18) 
-0.000 
-0.001 to 
0.000 
0.255 -0.003 
-0.008 to 
0.002 
0.251 
Antibiotics Filled Mean (SD)       
Number of guideline 
concordant antibiotics filled, 
first week in  episode of care 
0.37 
(0.51) 
0.44 
(0.53) 
0.39 
(0.52) 
0.51 
(0.53) 
0.032 
-0.022 to 
0.086 
0.238 0.189 
-0.030 to 
0.407 
0.091 
Number of antibiotics of 
concern filled, first week in 
episode of care 
0.38 
(0.52) 
0.34 
(0.50) 
0.33 
(0.49) 
0.34 
(0.50) 
-0.042 
-0.081 to 
-0.002 
0.039 -0.245 
-0.449 to 
-0.042 
0.018 
Paid Amounts Mean (SD)       
Standardized paid amounts, 
total episode of care 
246.85 
(255.56) 
242.84 
(244.24) 
217.95 
(257.57) 
248.53 
(249.7
4) 
-26.210 
-43.674 
to -8.745 
0.004 -154.058 
-192.087 
to  
-116.029 
0.000 
Standardized paid amounts 
for the first visit, total 
episode of care 
121.79 
(112.96) 
118.78 
(103.32) 
108.60 
(111.74) 
118.75 
(104.1
1) 
-10.941 
-18.022 
to -3.860 
0.003 -64.309 
-77.736 
to  
-50.882 
0.000 
Standardized paid amounts 
for follow-up care, total 
episode of care 
125.05 
(227.84) 
124.06 
(223.27) 
109.35 
(224.31) 
129.78 
(229.0
6) 
-15.269 
-26.051 
to -4.487 
0.006 -89.749 
-119.226 
to  
-60.273 
0.000 
N 37,223 9,171 82,356 19,693 148,163      
Note: Direct-to-consumer is abbreviated as DTC in the table above. All outcomes include health plan-product and year fixed effects. 
All standard errors are clustered at the health plan-product level. This analysis also contains only commercially-insured female 
patients enrolled in one of the treatment or comparison payer plans, with a urinary tract infection episode of care in the MN APCD, 
2009-2014. 
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Table 3-3. Stratified by age group: Instrumental variable results of association of DTC telemedicine-initiation with patient 
outcomes 
 Under 50    50 or older   
Service Categories Coefficient 95% CI p-value Coefficient 95% CI p-value 
Number of all services, total 
episode of care -0.710 -0.913 -0.508 0.000 -0.890 -1.399 -0.381 0.001 
Number of procedures, 
follow-up care -0.008 -0.034 0.017 0.523 0.058 -0.025 0.141 0.171 
Number of new office visits, 
follow-up care 0.011 -0.012 0.034 0.351 -0.008 -0.088 0.071 0.840 
Number of established office 
visits, follow-up care -0.255 -0.355 -0.156 0.000 -0.229 -0.473 0.016 0.067 
Number of other evaluation 
and management visits, 
follow-up care -0.000 -0.019 0.019 0.960 -0.004 -0.058 0.050 0.892 
Number of urinalysis tests, 
follow-up care -0.240 -0.310 -0.171 0.000 -0.306 -0.618 0.006 0.054 
Number of bacterial culture 
tests, follow-up care -0.084 -0.202 0.035 0.166 -0.233 -0.523 0.057 0.115 
Number of all other tests, 
follow-up care -0.122 -0.201 -0.044 0.002 -0.010 -0.211 0.192 0.925 
Any ED or Inpatient Care         
Any ED visits, follow-up care -0.097 -0.162 -0.033 0.003 -0.081 -0.206 0.043 0.200 
Any inpatient visits, follow-
up care -0.001 -0.004 0.003 0.770 -0.014 -0.041 0.013 0.300 
Antibiotics Filled         
Number of guideline 
concordant antibiotics filled, 
first week in episode of care -0.203 0.011 0.395 0.038 0.144 -0.261 0.549 0.486 
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Number of antibiotics of 
concern filled,  
first week in episode of care -0.256 -0.444 -0.067 0.008 -0.198 -0.550 0.154 0.270 
Paid Amounts         
Standardized paid amounts, 
total episode of care -146.742 -178.755 -114.729 0.000 -178.927 -292.678 -65.176 0.002 
Standardized paid amounts 
for the first visit, total episode 
of care -62.433 -75.252 -49.615 0.000 -66.063 -110.325 -21.502 0.004 
Standardized paid amounts 
for follow-up care, total 
episode of care -84.309 -109.271 -59.346 0.000 -112.864 -222.374 -3.353 0.043 
N 101,301    46,862    
Note: Direct-to-consumer is abbreviated as DTC in the table above. All outcomes include health plan-product and year fixed 
effects. All standard errors are clustered at the health plan-product level. This analysis also contains only commercially-
insured female patients enrolled in one of the treatment or comparison payer plans, with a urinary tract infection episode of 
care in the MN APCD, 2009-2014. 
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Table 3-4. Change in in-person, telemedicine, and overall evaluation and management visits for urinary tract infections 
 Coefficient 95% CI p-value 
Outcome     
Number of DTC Telemedicine Visits for UTI 0.189 0.034 0.343 0.018 
Number of In-person Visits for UTI -0.111 -0.279 0.058 0.195 
Total Visits for UTI 0.078 -0.173 0.329 0.535 
N 317    
Note: All results are represented as number of visits per 100 enrollees. Only evaluation and management visits were 
included in this analysis. Visits must have taken place in an office, outpatient setting, retail clinic, urgent care clinic, or 
via direct-to-consumer telemedicine. This analysis also contains only commercially-insured female patients enrolled in 
one of the treatment or comparison payer plans, with a urinary tract infection episode of care in the MN APCD, 2009-
2014. All outcomes include health plan-product and year fixed effects. All standard errors are clustered at the health 
plan-product level. 
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3.8. Appendix 
Overview 
In this appendix, we first described the methods for the main analysis in further detail, 
including how we derived standardize medical spending amounts, and the regression 
specifications for each of the models discussed in the main paper. We then described 
additional study results related to the direct comparisons of DTC telemedicine and in-
person initiated episodes of care, and study results for individuals with more than one 
UTI episode per year. 
 
Methods 
Data 
We used 2009-2014 health care claims data from the MN APCD. These data are 
derived from medical providers’ billing records that are sent to insurance companies, plan 
administrators and public payers (MDH, 2016). The claims data in the MN APCD 
represent health care claims for approximately 83% of the overall state population during 
the study years (MDH, 2016). The monthly health plan enrollment data is stripped of 
patient identifying information before it is submitted. A unique identifier is assigned to 
patients to permit analyses over time. The enrollment data file also contains payer 
identifiers, patient demographic information (e.g., age, sex) and zip code of residence.  
 
Study Sample 
We included all episodes of care for commercially insured, non-elderly female 
enrollees, initiated with a primary diagnosis for UTI or dysuria.  The condition dysuria is 
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included as an initial index condition along with a diagnosis of UTI, because patients 
may not be diagnosed with UTI but may present similar clinical indications as an UTI 
and is often equated with UTI by physicians (Bremnor & Sadovsky, 2002). The 
following ICD-9 and ICD-10 codes are used to define UTIs: 595.0, 595.9, 597.80, 599.0, 
N30.0, N30.00, N30.01, N30.9, N30.90, N30.91, N34.1, N34.2, N39.0, and dysuria: 
788.1, R30.0 (AFHSC, 2016). An additional restriction is that the first visit must also 
take place either through a DTC telemedicine visit, or at an office, urgent care clinic, 
outpatient facility, or retail health clinic. All follow-up claims may take place at any 
location. 
 
Medical Spending 
We created standardized medical prices for each service by finding the median 
price of all medical plan paid amounts for combinations of location (office, lab, clinic, 
outpatient, inpatient, other) and claim type (facility, professional) at the claim level, in 
the year 2014. The medical plan paid amounts are defined as the amount paid by the 
health plan for medical care, excluding patient out-of-pocket payments and withhold 
amounts. This approach resulted in ten mutually exclusive spending categories: 
professional office, professional lab, professional outpatient, professional clinic, 
professional inpatient, professional other, facility hospital outpatient, facility inpatient, all 
other categories, and DTC telemedicine. We used these standardized payment amounts 
for all years. The median paid amount for DTC telemedicine visits, 45 dollars, was used 
for all DTC telemedicine visits across all years. For all spending variables, we trimmed 
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the top and bottom one percent of all spending observations, to remove outliers that may 
skew the spending results. 
 
Statistical Analysis 
Difference-in-Differences Instrumental Variables First Stage  
A simple model of the relationships between our outcomes of interest and DTC 
telemedicine indication could be given as follows:  
(1)  𝑌𝑖t =∝ +𝛽 ∗ 𝐷𝑇𝐶𝑖t + 𝜃𝑋𝑖t + 𝛿t + 𝑖t  
In this episode-level regression equation, i represents episodes of care, and t 
represents years.  The indicator DTC takes on the value of one if a DTC telemedicine 
visit initiated the episode of care, and Y represents the outcome under consideration. 
Characteristics that vary at the episode-year level are represented by 𝑋𝑖t, and 𝛿t captures 
year fixed effects. Equation (1) would represent the impact of telemedicine use on 
follow-up care if individuals were randomized to using DTC care. This model however 
does not take confounders into account that affect both the decision to use DTC 
telemedicine services and the outcomes of interest. For instance, if individuals that 
choose to use DTC telemedicine typically have fewer medical complications related to 
the condition of interest, the coefficient of interest in equation (1), 𝛽1 may be biased 
towards finding that telemedicine use reduces overall utilization of services and medical 
expenditures. Instead, we used a difference-in-differences (DID) instrumental variables 
analysis. 
In the first stage of the DID instrumental variables analysis, we predicted DTC 
telemedicine initiation of an UTI episode of care. The DID regression is given by:   
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(2) 𝐷𝑇𝐶𝑖𝑝𝑦  𝛽𝑇𝑒𝑙𝑒𝑚𝑒𝑑𝑖𝑐𝑖𝑛𝑒𝐶𝑜𝑣𝑝𝑦 + 𝜃𝑋𝑖𝑦 + 𝛾𝑝 + 𝛿𝑦 + ε𝑖𝑝𝑦   
where each unit is indexed by episode i of health plan-product p in year y. The variable 
𝐷𝑇𝐶𝑖𝑝𝑦 takes on the value of 0 if the episode of care is initiated with an in-person visit, 
and 1 if the episode of care of initiated with a DTC telemedicine visit, and the variable 
TelemedicineCov is an indicator for whether or not a payer had expanded telemedicine 
coverage in a given year. This equation represents a standard DID analysis of the 
association of the entry and coverage of DTC telemedicine with telemedicine use, such 
that 𝛽 is the association of expanding telemedicine coverage with the increase of 
telemedicine initiated episodes of care. Additionally, the time-varying controls are 
contained within the vector 𝑋𝑖𝑦, and payer-health plan and year fixed effects are given 
by 𝛾𝑝 and 𝛿𝑦 respectively.   
This identification strategy relies on the assumption of parallel trends that treated 
and un-treated episodes of care follow similar patterns of growth in telemedicine use, 
and would have continued to do so had access to DTC telemedicine providers remained 
stable over the study period. A visual inspection of the trends among selected outcomes 
(number of services, standardized spending amounts, antibiotics of concern) for the 
treatment and comparison groups supports the parallel trends assumption that the growth 
in these outcomes would have followed similar paths even in the absence of the entry 
and coverage of the DTC telemedicine providers (Appendix Exhibit 3-7). Additionally, 
we did not see differences in the severity of UTI episodes in the treatment payers relative 
to the comparison payers (Table 3-2) in the pre-period.  
We also investigated whether the treatment and control groups exhibited 
statistically significant different trends in the pre-period by including leads, or 
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interactions of year and treatment dummies in the pre-period (Appendix Exhibit 3-8). 
The coefficients for these interaction terms do not significantly differ from zero in the 
pre-treatment period for all outcome variables with the exception of guideline-
concordant antibiotics prescribed. For this outcome variable, payer specific initiatives to 
lower antibiotics use may have led to differing trends in antibiotics filled in the pre 
period between episodes of care in the treatment and comparison groups. Altogether 
these tests provided confidence that the parallel trends assumption is met for all other 
outcomes.   
 
Instrumental Variables Second Stage   
The reduced form regression of the association between telemedicine use and 
utilization, cost, and quality outcomes is given by:     
(3) 𝑌𝑖𝑝t  𝜇𝑇𝑒𝑙𝑒𝑚𝑒𝑑𝑖𝑐𝑖𝑛𝑒𝐶𝑜𝑣𝑝𝑦 + 𝜃𝑋𝑖t + 𝛾𝑝 + 𝛿t + ε𝑖𝑝t  
We can interpret the coefficient 𝜇 in equation 3 as the intent-to-treat analysis of 
telemedicine coverage on health outcomes. The estimate of the overall association of an 
initial DTC telemedicine service with quality, utilization, and spending outcomes over 
the episode of care among the individuals affected by the entry and coverage of DTC 
telemedicine services is given by the ratio of 𝜇/𝛽.  This Wald-DID estimator identifies 
the local average treatment effect (LATE) of compliers, or in the context of this study, 
individuals enrolled in a treatment group health plan product that utilized DTC 
telemedicine services for UTIs in the post period. This LATE can also be given by a 
2SLS specification, where we first use the DID model in the first stage to estimate the 
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predicted telemedicine initiation of an episode of care, and regress the outcomes of 
interest on predicted telemedicine initiation in the second stage:  
(4) 𝑌𝑖𝑝t =∝ + 𝛽𝑇𝐼 ̂𝑝t + 𝜃𝑋𝑖t + 𝛾𝑝 + 𝛿t + ε𝑖𝑝t  
In this specification, 𝑇𝐼 ̂𝑝𝑡 is the predicted telemedicine initiation of an episode of care 
given by equation 2, and 𝑌𝑖𝑝t is the quality, utilization, or spending outcome variable of 
interest.  
  
Telemedicine Visits as Substitutes for In-person Visits  
In the second part of this study, we examined whether telemedicine visits may be 
substituting in-person care or constitutes new utilization, by evaluating the change in the 
number of in-person, DTC telemedicine visits, and visits overall for UTI from the pre 
period 2009-2010, to the 2011-2014 period. We used a DID model to estimate an overall 
differential change in the total number of in-person and telemedicine care visits per 10,000 
enrollees for individuals diagnosed with UTI. This is given by the regression:  
(5)  Visitsp𝑦 =∝ +𝛽𝑇𝑒𝑙𝑒𝑚𝑒𝑑𝑖𝑐𝑖𝑛𝑒𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒p𝑦 + 𝛿𝑦 + εp𝑦  
where Visitsp𝑦 represents the number of in-person and telemedicine visits in each treatment 
payer-health plan p in each year y.  
 
Additional Results 
Compared to female patients utilizing in-person initiated episodes of care for 
UTI, female patients utilizing DTC telemedicine episodes of care were more likely to be 
in the 25 to 34 age category (33.0% vs 19.31%), more likely to live in a metropolitan 
area (80.7% vs 59.7%), and less likely to be a high cost user (5.80% vs 9.40%) 
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(Appendix Exhibit 3-4). Individuals in the treatment and comparison groups within the 
instrumental variables analysis are more aligned across these patient-level variables than 
telemedicine and non-telemedicine users, giving us some confidence that our approach 
addresses some confounders (Table 3-2).  
We constructed a multivariate regression model to examine the association 
between a DTC telemedicine-initiated episode of care and the outcomes of interest. 
Results indicated that telemedicine initiation of an episode of care was associated with 
fewer overall services (-0.86; 95% CI: -0.89,-0.83; P< .001) and lower standardized 
payment amounts (-169.37; 95% CI: -175.88, -162.85; P< .001) (Appendix Exhibit 3-6). 
These reductions in services and standardized medical spending over an episode of care, 
decreased in magnitude when we applied the instrumental variables model, but remained 
negative and statistically significant. DTC telemedicine initiation was also associated 
with more guideline concordant antibiotics filled (0.36; 95% CI: 0.34, 0.38; P <.001), 
and fewer antibiotics of concern filled (-0.20; 95% CI: -0.22, -0.19; P <.001) (Appendix 
Exhibit 3-6). We again see the same patterns in the instrumental variable model results 
(Table 3-2).  
Finally, we found a similar pattern of results for the subset of individuals with 2 
or more diagnoses of UTI relative to the overall instrumental variable results (Appendix 
Exhibit 3-5). However, the outcomes related to antibiotics filled, other tests, and ED use 
are no longer statistically significant, and the probability of having any inpatient visit for 
individuals with two or more UTIs in a year using DTC telemedicine is negative and 
statistically significant (-0.01; 95% CI: -0.20, -0.00; P= 0.04).   
 
84 
Appendix Exhibit 3-1. ICD-9 and ICD-10 Diagnosis codes appearing in an urinary 
tract infection episode of care 
ICD-9         
590 590.01 590.1 590.1 590.2 590.3 590.8 590.80 590.81 590.9 
593.6 593.7 593.71 593.72 593.73 593.8 593.81 593.82 593.89 593.9 
595.4 595.8 595.81 595.82 595.89 595.9 596 596.1 596.2 596.3 
596.8 596.81 596.82 596.83 596.89 596.9 597 597.8 597.81 597.89 
599.4 599.5 599.6 599.69 599.7 599.71 599.72 599.8 599.81 599.82 
788.31 788.32 788.33 788.34 788.35 788.36 788.37 788.38 788.39 788.4 
788.69 788.7 788.8 788.9 788.91 788.99     
 591 592 592.1 592.9 593 593.1 593.2 593.3 593.4 593.5 
594 594.1 594.2 594.8 594.9 595 595.1 595.2 595.3 595.4 
596.4 596.5 596.51 596.52 596.53 596.54 596.55 596.59 596.6 596.7 
598 598.01 598.1 598.2 598.8 598.9 599 599.1 599.2 599.3 
599.83 599.84 599.89 599.9 788.1 788 788.2 788.21 788.29 788.3 
788.41 788.42 788.43 788.5 788.6 788.61 788.62 788.63 788.64 788.65 
ICD-10        
N30  N30.01 N30.1 N30.11 N30.2 N30.21 N3.03 N30.31 N30.4 N30.41 
N32.1 N32.2 N32.3 N32.8 N32.81 N32.89 N32.9 N33 N34 N34.1 
 N35.028 
      
N35.1  N35.12  N35.8  N35.82  N35.9  N35.92 N36  N36.1  N36.2 
N39.3  N39.4  N39.41  N39.42  N39.43  N39.44  N39.45  N39.46  N39.49 
 
N39.491 
R31.21  R31.29  R31.9 R32 R33 R33.8 R33.9 R34 R35 R35.1 
R39.14 R39.15 R29.16 R29.19 R39.191 R39.192 R39.198 R39.2 R39.8 R39.81 
N30.8 N30.81 N30.9 N30.91 N31  N31.1 N31.2 N31.8 N31.9 N32 
N34.2 N34.3 N35 
 
N35.011 
 
N35.012 
 
N35.013 
 
N35.014 
 
N35.016  N35.02 
 
N35.021 
 N36.4  N36.41  N36.42  N36.43  N36.44  N36.5  N36.8 N36.9 N37 N39 
 N39.492 
 
N39.498  N39.8 N39.9 R30  R30.1  R30.9 R31 R31.1  R31.12 
R35.8 R36 R36.1 R36.9 R37 R39 R39.1 R39.11 R39.12 R39.13 
R39.82 R39.83 R39.84 R39.89 R39.9      
          
Note: The bolded ICD-9 and ICD-10 codes are used to identify UTIs and Dysuria 
diagnoses  
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Appendix Exhibit 3-2. Sequence of index and follow-up services for urinary tract 
infection episodes of care 
 
 
 
 
 
 
Note: This figure depicts the sequential steps that start with an individual having an 
initial health event. They may either seek care through an initial index DTC 
telemedicine service or through an in-person care service. This marks the first day 
of the 30-day episode of care during which additional follow-on services may 
occur. Antibiotics are assessed within the first week of the 30-day episode.  
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Appendix Exhibit 3-3. Urinary tract infection episodes of care in treatment and 
comparison groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enrollees of plan products within 
payers not covering DTC 
telemedicine 
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Appendix Exhibit 3-4. Characteristics of Telemedicine and Non-Telemedicine initiated 
episodes of care  
Variable 
In-person 
initiated episode 
Telemedicine 
initiated episode 
Age Category (%)   
Age, 0-18 3.02 0.69 
Age, 19-24 16.06 11.43 
Age, 25-34 19.31 32.99 
Age, 35-44 18.42 24.59 
Age, 45-54 21.77 19.21 
Age, 55-64 21.43 11.09 
Probability of High User 9.40 5.80 
Number of chronic conditions 1.60 1.17 
Percent of Medicare beneficiaries 
with one or more visits to a primary 
care physician annually in ZIP code 71.06 92.39 
Percent with bachelors degree or 
higher in ZIP code 32.77 38.44 
Percent below federal poverty level 
in the past 12 months in ZIP code 10.12 9.52 
Percent with private insurance in 
ZIP code 78.75 78.57 
Lives in a metropolitan area 59.66 80.74 
Chronic conditions (%)   
Bipolar disorder 0.94 0.77 
Congestive heart failure 1.68 2.08 
COPD 0.39 0.06 
Chronic renal failure 0.61 0.12 
Depression 30.63 29.22 
Diabetes 5.92 2.84 
Hypertension 18.67 12.84 
Ischemic heart disease 0.59 0.21 
Persistent asthma 13.37 12.52 
Rheumatoid arthritis 2.01 0.70 
Low back pain 18.65 13.93 
N 130,825 17,338 
Note: This sample contains only commercially-insured female patients enrolled in one of 
the treatment or comparison payer plans, with a urinary tract infection episode of care in 
the MN APCD, 2009-2014. 
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Appendix Exhibit 3-5: Individuals with recurring urinary tract infections: Instrumental variable results of the 
association of direct-to-consumer telemedicine-initiation with patient outcomes 
Service Categories Coefficient 95% CI p-valuee 
Number of all services, total episode of care -0.682 -1.033 -0.330 0.000 
Number of procedures, follow-up care 0.015 -0.029 0.058 0.509 
Number of new office visits, follow-up care 0.015 -0.041 0.070 0.609 
Number of established office visits, follow-up care -0.350 -0.516 -0.184 0.000 
Number of other evaluation and management visits, 
follow-up care 
-0.005 -0.043 0.034 0.816 
Number of urinalysis tests, follow-up care -0.251 -0.411 -0.091 0.002 
Number of bacterial culture tests, follow-up care -0.013 -0.220 0.194 0.904 
Number of all other tests, follow-up care -0.039 -0.184 0.107 0.602 
Any ED or Inpatient Care     
Any ED visits, follow-up care -0.125 -0.256 0.006 0.061 
Any inpatient visits, follow-up care -0.010 -0.020 -0.000 0.042 
Antibiotics Filled     
Number of guideline concordant antibiotics filled, total 
episode of care 
0.087 -0.046 0.220 0.201 
Number of antibiotics of concern filled, total episode of 
care 
-0.234 -0.544 0.076 0.138 
Paid Amounts     
Standardized paid amounts, total episode of care -134.610 -211.969 -57.251 0.001 
Standardized paid amounts for the first visit, total episode 
of care 
-65.934 -109.127 -22.741 0.003 
Standardized paid amounts for follow-up care, total 
episode of care 
-68.676 -133.101 -4.251 0.037 
N 105,762    
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Note: All outcomes include health plan-product and year fixed effects. All standard errors are clustered at the health  
plan-product level. This sample contains only commercially-insured female patients enrolled in one of the treatment or comparison 
payer plans, with a urinary tract infection episode of care in the MN APCD, 2009-2014. 
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Appendix Exhibit 3-6. Association between direct-to-consumer telemedicine initiation and episode-level outcomes 
Service Categories Coefficient              95% CI p-value 
Number of all services, total episode of care -0.859 -0.893 -0.826 0.000 
Number of procedures, follow-up care -0.009 -0.010 -0.008 0.000 
Number of new office visits, follow-up care -0.035 -0.044 -0.026 0.000 
Number of established office visits, follow-
up care 
-0.268 -0.279 -0.258 0.000 
Number of other evaluation and management 
visits, follow-up care 
0.003 0.002 0.004 0.000 
Number of urinalysis tests, follow-up care -0.239 -0.262 -0.216 0.000 
Number of bacterial culture tests, follow-up 
care 
-0.154 -0.160 -0.149 0.000 
Number of all other tests, follow-up care -0.094 -0.097 -0.092 0.000 
Any ED or Inpatient Care     
Any ED visits, follow-up care -0.057 -0.061 -0.052 0.000 
Any inpatient visits, follow-up care -0.001 -0.001 0.000 0.000 
Antibiotics Filled     
Number of guideline concordant antibiotics 
filled, first week in episode of care 
0.362 0.342 0.383 0.000 
Number of antibiotics of concern filled, first 
week in episode of care 
-0.204 -0.219 -0.189 0.000 
Paid Amounts     
Standardized paid amounts, total episode of 
care 
-169.366 -175.883 -162.849 0.000 
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Standardized paid amounts for the first visit, 
total episode of care 
-76.611 -81.596 -71.626 0.000 
Standardized paid amounts for follow-up 
care, total episode of care 
-92.755 -94.622 -90.887 0.000 
N 148,163    
Note: All outcomes include health plan-product and year fixed effects. All standard errors are clustered at the health  
plan-product level. This analysis contains only commercially-insured female patients enrolled in one of the treatment or 
comparison payer plans, with a urinary tract infection episode of care in the MN APCD, 2009-2014. 
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Appendix Exhibit 3-7. Unadjusted Trends in Selected Outcomes over Time 
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Note: All outcomes in the first year are tested against outcomes in the second year. All 
outcomes include health plan-product and year fixed effects. All standard errors are 
clustered at the health plan-product level. This analysis contains only commercially-
insured female patients enrolled in one of the treatment or comparison payer plans, 
with a urinary tract infection episode of care in the MN APCD, 2009-2014. 
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Appendix Exhibit 3-8. Testing Parallel Trends in the Pre-period 
Outcomes Interaction p-value 
Number of all services, total episode of care -0.039 0.243 
Number of procedures, follow-up care -0.002 0.502 
Number of new office visits, follow-up care -0.006 0.123 
Number of established office visits, follow-up care 0.000 0.957 
Number of other evaluation and management visits, 
follow-up care 
0.002 0.127 
Number of urinalysis tests, follow-up care -0.019 0.259 
Number of bacterial culture tests, follow-up care -0.013 0.433 
Number of all other tests, follow-up care -0.010 0.391 
Any ED or Inpatient Care   
Any ED visits, follow-up care 0.006 0.164 
Any inpatient visits, follow-up care 0.001 0598 
Antibiotics Filled   
Number of guideline concordant antibiotics filled, first 
week in episode of care 
-0.054 0.002 
Number of antibiotics of concern filled, first week in 
episode of care 
-0.041 0.111 
Paid Amounts   
Standardized paid amounts, total episode of care 5.829 0.169 
Standardized paid amounts for the first visit, total episode 
of care 
1.620 0.604 
Standardized paid amounts for follow-up care, total 
episode of care 
4.209 0.141 
N 148,163  
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4. Chapter 3: Did a Statewide Parity Law for Telemedicine Services Expand 
Telemedicine Use for Medicaid Patients? 
Jiani Yu 
 
Prepared for submission to Health Services Research 
 
4.1. Synopsis  
 
Objective. To investigate whether a statewide parity law in Minnesota that mandated 
equal reimbursement for telemedicine and in-person services in 2016 for Medicaid 
enrollees was associated with increased telemedicine use among Medicaid patients. I first 
examined changes in the volume and types of telemedicine services utilized. I then 
assessed whether the policy change led to an increase in the overall use of telemedicine 
services among Medicaid enrollees relative to a comparison group of Medicare enrollees. 
 
Data Sources. The Minnesota All Payer Claims Database (MN APCD) from 2010 to 
2016.  
 
Study Design. I estimated pre-post differences in the volume and types of telemedicine 
services utilized by Medicaid enrollees after the implementation of the statewide 
telemedicine parity law. I also used difference-in-differences models to estimate relative 
changes in per capita telemedicine use after the passage and implementation of the 
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telemedicine parity policy affected per capita telemedicine use among Medicaid enrollees 
relative to a comparison group of Medicare enrollees in small towns and rural areas.   
 
Principal Findings. From 2010 to 2016, telemedicine visits within the Medicaid 
population in Minnesota increased from 972 to 4,490 total visits. The number of unique 
providers supplying telemedicine visits increased from 1.59 percent of all unique 
providers in 2010 data, to 4.41 percent in 2016. For common telemedicine procedures, 
reimbursements for telemedicine visits were similar to those of in-person visits after the 
MTA. However, in previous years, average reimbursements for telemedicine visits were 
higher than those for in-person visits. The number of telemedicine visits for mental 
health conditions within the Medicaid population increased relative to the Medicare 
comparison group following passage of the statewide parity law in 2015 (0.012; 
p<0.001), as well as in 2016 (0.013, p<0.001) 
 
Conclusion. Observed average reimbursement rates for common telemedicine procedures 
and their in-person equivalents for Medicaid enrollees in Minnesota were similar in 2016, 
but average telemedicine reimbursements were higher in previous years. The use of 
telemedicine among Medicaid enrollees for mental health services in small towns and 
rural areas increased relative to Medicare enrollees, but there was no change in the use of 
telemedicine for all other services, after the implementation of the telemedicine parity 
law.  
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4.2. Introduction 
 
In the United States, more than 47 million Americans live in rural areas, where 
individuals face geographic barriers to health, provider shortages, and often higher costs 
of care compared to urban areas ("New Census Data Show Differences Between Urban 
and Rural Populations," 2016). Approximately 21% of the United States population 
lives in a primary care Health Professional Shortage Areas (HPSAs), based on 
population-to-provider ratios, and 44% living in a mental health HSPA ("Primary Care 
Health Professional Shortage Areas (HPSAs)," 2016). The majority of HPSAs are 
found in rural regions, which may contribute to the higher rates of mortality and lower 
health status of individuals residing in rural relative to urban areas (Michael Meit, 
2014; "Shortage Areas," 2019).  
Telemedicine, or providing health services from a distance, has the potential to 
improve access to care in underserved areas (MedPAC, 2016). Recent studies have 
shown that telemedicine may improve access to primary care and reduce hospitalizations, 
and has been used for Medicare enrollees to treat chronic conditions such as end-stage 
renal disease (MedPAC, 2018). Recent federal legislation is also expanding Medicare 
coverage of telemedicine services to include the treatment of strokes in urban areas 
(MedPAC, 2018). The use of telemedicine for mental health services (“telemental 
services”), in particular, has experienced the most substantial growth compared to other 
telemedicine services (Douglas et al., 2016; Gilman & Stensland, 2013; Mehrotra et al., 
2017; Mehrotra et al., 2016; Neufeld & Doarn, 2015; Yu, Mink, Huckfeldt, Gildemeister, 
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& Abraham, 2018). Telemental services have primarily been used to deliver medication 
management, psychotherapy, and other mental health consultations, including for the 
treatment of substance abuse disorders (Chan, Parish, & Yellowlees, 2015; Huskamp et 
al., 2018; MedPAC, 2016). As roughly 96 percent of counties in the United States have a 
shortage of psychiatrists, and one in five counties in the nation have a shortage for non-
physician mental health providers, these telemedicine services may help to mitigate the 
high rate of unmet need for mental health care services (MedPAC, 2018; Thomas, Ellis, 
Konrad, Holzer, & Morrissey, 2009).  
Despite substantial increases in telemedicine utilization in recent years, the 
overall use of telemedicine is still very low in absolute terms across different coverage 
populations, and a number of barriers exist to the widespread use of telemedicine 
(Dorsey & Topol, 2016; Yu et al., 2018). One leading barrier to more widespread 
telemedicine use is the lack of uniform reimbursement to providers for supplying care 
through telemedicine (Dorsey & Topol, 2016). In the United States, there is significant 
variation across states in terms of which telemedicine services are reimbursed by which 
payers and how (Trout, Rampa, Wilson, & Stimpson, 2017).  
Currently, some 47 states have Medicaid coverage for real-time services, or live-
audiovisual telemedicine visits, while 37 have policies for store-and-forward services, or 
the collection and transmission of medical data between providers (MedPAC, 2016; 
Trout et al., 2017). Medicaid parity laws that require telemedicine services to be 
reimbursed at the same rate as in-person equivalent services have been passed in 13 
states (Trout et al., 2017). Recent work by Wilson et al. determined that average 
98 
 
reimbursements for telemedicine services were significantly lower in states without 
telemedicine parity laws, compared to those for non-telemedicine services for seven of 
the ten most common services (Wilson, Trout, Rampa, & Stimpson, 2016). These results 
suggest that the provision of telemedicine services may be hampered by lower 
reimbursements for telemedicine services relative to face-to-face service delivery.  
The evidence in the literature on whether state telemedicine policies drive the 
provision of telemedicine services is mixed. Several studies in the past few years have 
found that state parity policies are associated with more telemedicine use (Harvey, 
Valenta, Simpson, Lyles, & McElligott, 2019; Mehrotra et al., 2017; Mehrotra et al., 
2016; Neufeld, Doarn, & Aly, 2016). For instance, one study found that telemedicine 
visits for Medicare enrollees in one state increased by 118 percent after the passage of 
telemedicine parity legislation affecting commercial payers (Neufeld et al., 2016). 
Another study found that in states with parity laws, telemedicine outpatient visits 
increased within a commercially insured population (Harvey et al., 2019). Mehrotra et al. 
also found that the rate of telemedicine visits for mental health services among Medicare 
beneficiaries was higher in states with private parity laws although the per capita growth 
of telemedicine was similar between parity and non-parity states (Mehrotra et al., 2017; 
Mehrotra et al., 2016).  
Using data from the American Medical Association’s 2016 Physician Practice 
Benchmark Survey, other recent work found that were was no association between 
telemedicine use overall and state parity laws, although the authors stated that a more 
focused analysis on a subset of services may show differences in telemedicine use across 
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states with different parity laws (Kane & Gillis, 2018). Similarly, Park et al. did not find 
any significant association between state parity laws and telemedicine use after 
controlling for patient characteristics, including race and ethnicity, insurance coverage, 
and self-reported health characteristics (Park, Erikson, Han, & Iyer, 2018).  
While other studies have looked broadly at state parity laws in the United States, 
this is the first to examine the implications of an expansion in parity legislation for 
telemedicine services for the Medicaid enrollee population relative to a Medicare 
comparison group of enrollees within a state. By using within state comparison groups, 
this study reduced sources of bias from state secular trends that may have affected 
previous analyses looking across states. I leveraged the Minnesota All-Payer Claims 
Database (MN APCD) to compare telemedicine utilization between multiple payers 
within Minnesota.  
The state parity law in Minnesota, the Minnesota Telemedicine Act (MTA), 
passed in June 2015, mandated reimbursement parity for all health care services provided 
via telemedicine technologies for Medicaid beneficiaries (implemented January 2016) 
("Coverage of Telemedicine Services," 2015). Reimbursement parity requirements 
expanded to include commercial enrollee populations shortly thereafter (implemented 
January 2017) ("Coverage of Telemedicine Services," 2015). Even prior to the MTA 
however, mental health care services delivered via telemedicine by physicians were 
already being reimbursed at parity with in-person services Medicaid enrollees starting in 
2006 ("Minnesota Statutes Annotated - 2007," 2007). However, the MTA expanded the 
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types of providers that could deliver telemental services, and may have facilitated 
renewed attention to telemedicine services in the state.  
The scope of this policy change allowed for a quasi-experimental study design, as 
the variation in exposure to the reimbursement policy differs across coverage populations 
and years. I first estimated pre-post analyses to descriptively show the changes in 
telemedicine use within the Medicaid population after the passing and implementation of 
the MTA. In these analyses, I examined the changes in telemedicine use across 
metropolitan and nonmetropolitan areas; across provider specialties and provider types; 
and for mental and non-mental health conditions. 
Next, I evaluated whether there were differential changes in telemental and non-
telemental use after the MTA went into effect, for the Medicaid population relative to a 
comparison population derived from Medicare enrollees in MN in small towns and rural 
areas. These findings provided some initial evidence as to whether telemedicine 
reimbursement parity has the potential to expand the telemedicine use in non-
metropolitan areas. 
 Finally, I examined whether this policy change led to an expansion in the overall 
number of mental health and non-mental health services for individuals living in small 
towns and rural areas.  
 
Potential Outcomes Related to Telemedicine Parity Policy 
Given current evidence on telemedicine parity laws, it remains unclear whether 
the MTA led to growth in the volume and types of telemedicine services, and improved 
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access to care in underserved areas. On the one hand, a parity policy may improve the 
supply of telemedicine services by physicians and/or other provider types, if more 
providers deliver telemedicine services in response to higher reimbursement rates.  
Improved provider reimbursements for telemedicine may motivate more providers 
to invest in the fixed costs of telemedicine technologies, along with the training and 
staffing requirements related to providing telemedicine services. Past studies have 
concluded that providers respond positively to increased payment rates by investing in 
physical and human capital (Clemens & Gottlieb, 2014; Finkelstein, 2007). Although the 
costs of purchasing telemedicine hardware may be prohibitive, with a telemedicine 
mobile cart and hardware for primary care starting from around $20,000 per site, the 
costs of delivering virtual care by providers, relative to traditional modes of care, may be 
less resource intensive (AMD, 2015). For instance, Medicare telemedicine codes have 
Relative Value Units (RVU) of 1.17 for a 30 minute telemedicine consultation, compared 
to an in-person evaluation and management visit, which receives a RVU of 1.76 
("Physician Fee Schedule 2019 Final Rule," 2018). It’s unclear therefore empirically, 
how the MTA may impact the breadth and volume of telemedicine services.  
Some recent evidence from Medicaid and Medicare reimbursement changes also 
suggest that physician behavior should respond to changes in payment (Alexander & 
Schnell, 2017; Neprash, 2017). Alexander and Schnell found that a federally mandated 
increase in Medicaid reimbursements led more providers to see Medicaid patients, but 
did not appear to draw physicians away from non-Medicaid populations on the extensive 
margin (Alexander & Schnell, 2017). In other work looking at the impact of higher 
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Medicaid reimbursements on physician labor supply, Neprash finds preliminary evidence 
that physicians seeing Medicaid patients increased the total number of appointments, 
which may have resulted in decreased appointment lengths (Neprash, 2017). Another 
paper showed that a decrease in Medicare payments for surgeons lead to more overall 
patient hours, and a shift away from investing in professional activities (Clemens, 
Gottlieb, & Hicks, 2018).  
Because a parity law already existed in Minnesota for telemental health visits 
delivered by physicians, telemental health visits should be less affected by the MTA, all 
else equal. The expanded provider scope of the MTA, may encourage however, more 
provision of telemental visits among all non-physician mental health providers. 
Nevertheless, mental health telemedicine likely has the lowest fixed cost barriers 
compared to other specialties, requiring primarily videoconferencing equipment 
(Shannon Mace, 2018). Additionally, given the previous parity policy for telemedicine 
and mental health care, provider organizations may already have existing infrastructure, 
knowledge, and technologies for supplying telemental visits.  
Required parity payments for telemedicine services may also affect the provision 
of in-person care. For instance, in-person visits may decrease if more providers substitute 
in-person care with telemedicine care as a result of payment parity. Alternatively, the 
parity law may also lead to an expansion in total in-person health care services if 
reimbursement parity expands access to individuals who did not previously use care, or 
encourages the provision of unnecessary or low-value care (Ashwood, Mehrotra, 
Cowling, & Uscher-Pines, 2017; Yang, 2016). The overall association of the MN 
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statewide parity law on the provision of telemedicine visits in non-metropolitan areas, 
and on the use of in-person health care services, therefore requires an empirical 
investigation of the policy change.  
 
4.3. Data and Methods 
 
Data Source 
This study used 2010-2016 health care claims data from the MN APCD. The MN 
APCD is a state repository of de-identified health care claims data, and contains 
integrated medical claims, pharmacy claims, and plan enrollment data across commercial 
and public payers in Minnesota (MDH, 2016). These data are derived from medical 
providers’ billing records that are sent to insurance companies, plan administrators and 
public payers (MDH, 2016). The public health plans represented in the MN APCD 
include Medicaid fee-for-service, Medicaid managed care, Medicare fee-for-service, and 
Medicare Advantage plans (MDH, 2016).  
The claims captured in the MN APCD for the study years represent health care 
claims for approximately 89% of Minnesotans with health care coverage (MDH, 2016). 
The monthly health plan enrollment data for individuals in the MN APCD are stripped of 
patient identifying information before it is submitted, but a unique identifier is assigned 
to patients to permit analyses over time (MDH, 2016). The enrollment data file also 
contains payer identifiers, patient demographic information (e.g., age, sex) and zip code 
of residence (MDH, 2016).  
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I linked the Rural-Urban Commuting Area (RUCA) code data with the MN 
APCD to provide rural-urban classification, and the National Uniform Claim Committee 
(NUCC) Taxonomy Codes to supply provider specialty information (NUCC, 2018; 
RUCA Data, 2005). I also used the AHRQ Clinical Classifications Software (CCS) for 
diagnosis classification, in order to aggregate primary diagnosis codes on the MN APCD 
medical claims into mutually exclusive clinical categories (AHRQ, 2018). 
 
Study Sample 
The MTA policy was implemented in 2016 for Medicaid enrollees in Minnesota 
Health Care Programs, so this study focused on the change in telemedicine services 
within this coverage population only. Minnesota Health Care Programs include Medical 
Assistance (Minnesota’s Medicaid program for people with low income) and 
MinnesotaCare (a health care program for Minnesotans with low incomes). In this paper, 
I refer to these programs collectively as “Medicaid.” In the first analysis to assess the 
change in the volume and types of telemedicine services utilized before and after the 
implementation of the MTA, I examined both adult and pediatric Medicaid populations. 
In the second part of the study, I included only individuals enrolled in Medicaid 
aged 55-64 in the treatment group, and Medicare enrollees aged 65-70 in the comparison 
group, in order to compare enrollees across the two groups that were similar in terms of 
age. Dually eligible enrollees were excluded. During the study period, telemedicine visits 
were covered for only Medicare enrollees receiving care in rural HSPAs and counties 
outside a Metropolitan Statistical Area (MLN, 2019). There were no policy changes for 
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the reimbursement of telemedicine services for Medicare enrollees during the study years 
however, and these enrollees were not directly affected by the Minnesota policy change. 
Because telemedicine visits are covered for Medicare only in nonmetropolitan areas, I 
examined the changes in telemedicine utilization for individuals in small towns and rural 
area ZIP codes only. In the final analysis, I evaluated the change in in-person mental and 
non-mental health services also for individuals in small towns and rural area ZIP codes. 
 
Identifying Telemedicine Visits  
Telemedicine can be broadly grouped into three categories: (1) provider-initiated 
visits, (2) patient-initiated direct-to-consumer visits, and (3) remote patient monitoring. 
The MTA applied specifically to the first category, which includes provider-initiated real-
time, or live audiovisual telemedicine visits, provider-initiated store-and-forward 
services, other provider-initiated telemedicine consultations, and provider-initiated 
telemedicine pharmacologic management. I identified telemedicine visits in the MN 
APCD in two ways. First, I flagged Current Procedure Terminology (CPT) modifier 
codes that are used to bill for telemedicine services. Specifically, the modifier code GT is 
used to bill for provider-initiated, real-time audiovisual telemedicine services, and the 
code GQ is used to bill for provider-initiated store and forward telemedicine services. 
Second, I flagged telemedicine-specific CPT codes in the medical claims file to identify 
additional telemedicine services which do not require a procedure modifier code. These 
are the CPT codes G0425, G0426, G0427 for emergency department (ED) and initial 
inpatient consultations, G0406, G0407 for follow-up inpatient and skilled nursing facility 
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consultations, G0508, G0509 for critical care consultations, and G0459 for 
pharmacologic management services (CMS, 2019). I aggregated all claims with or 
without a telemedicine identifier into unique encounters using a combination of the first 
and last service dates, the attending provider’s NPI, and the individual’s patient identifier.  
 
Outcome Variables 
I first assessed the change in the volume and types of telemedicine services 
provided within the Medicaid population after the implementation of the MTA, by 
examining the total number of unique telemedicine encounters, the number of unique 
telemedicine users, the suppliers of telemedicine, and diagnosis categories. To categorize 
the suppliers of telemedicine, I subset all telemedicine claims into 1) provider 
specialties: Family and Internal Medicine, Mental Health, Nephrology and 
Endocrinology, Rural and Critical Access, Neurology, Sleep Medicine, and other; 2) 
provider types: Doctor of Medicine/Doctor of Osteopathic Medicine (MD/DO), Nurse 
Practitioner (NP), Physician Assistant (PA), Licensed Social Worker (LICSW), 
Registered Nurse (RN), and other. For diagnosis categories, I subset telemedicine 
encounters into alcohol and other substance use disorders, mood and anxiety disorders, 
dementia and related disorders, schizophrenia and other psychotic disorders, other 
mental health disorders, chronic kidney disease and end stage renal disease, diabetes, and 
other.  
I also assessed the average reimbursements, or the medical plan paid amounts for 
procedure codes that are commonly billed as telemedicine services. The medical plan 
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paid amounts are what the health plan pays providers for medical care only, excluding 
any patient out-of-pocket payments (MDH, 2016). Specifically, I examined two 
evaluation and management (E&M) procedures (99213, 99214), and a 30-minute 
psychotherapy visit (90833). Each procedure was shown by fee-for-service versus 
managed care plans due to the difference in negotiated payments for each type of plan. 
For the E&M procedures, I further subset average reimbursements into psychiatry 
specialties (physicians only), and non-psychiatry specialties (all provider types), as 
telemedicine psychiatric services delivered by physicians should have been reimbursed 
at parity starting in 2006. 
Next, I examined the per capita change in the number of telemental and non-
telemental health services among the Medicaid enrollee sample relative to the 
comparison group of Medicare enrollees, in small towns and rural areas. The claims for 
mental health services have a primary diagnosis for a mental health condition, as well as 
a procedure code pertaining to an evaluation and management code, psychotherapy 
services, psychiatric diagnostic interviews, and medication management (Appendix 
Exhibit 4-1). The non-mental health visits do not contain a primary diagnosis for a 
mental health condition, nor a procedure code for one of these mental health services, 
and should not have been covered for any provider types at parity prior to the enactment 
of the MTA. Finally, I evaluated the change in the per person number of in-person visits 
for mental health and non-mental health services for individuals living in small towns 
and rural areas, in order to examine if a decrease in in-person services coincided with the 
implementation of the MTA. 
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Control Variables 
I controlled for the patient’s age, individual comorbidities (congestive heart 
failure, depression, bipolar disorder, diabetes, hypertension, ischemic heart disease, 
persistent asthma, rheumatoid arthritis, schizophrenia, chronic obstructive pulmonary 
disorder, chronic renal failure, low back pain), the total number of comorbidities, and the 
probability of being a persistent high cost user, which corresponds to whether someone is 
likely to be in the top quintile in terms of costs among the overall population sample for 
two consecutive years (“The Johns Hopkins ACG® System Excerpt”, 2014). 
Information on comorbidities was derived from the Johns Hopkins ACG® system, where 
an algorithm requiring more than one diagnosis code for certain chronic conditions over 
a time period, was applied to determine a patent’s comorbidities (“The Johns Hopkins 
ACG® System Excerpt”, 2014). I determined the rurality of a patient’s ZIP code based 
on the plurality of each patient’s ZIP codes in each year in metropolitan, micropolitan, 
small towns, and rural areas (“RUCA Data", 2005).  
 
Analysis of the Change in Telemedicine Services within the Medicaid Comparison Group 
I first showed the changes in the total volume of unique telemedicine encounters 
and the number of unique telemedicine users before and after the implementation of the 
MTA. I also showed these changes as a percentage of all Medicaid enrollees, and all 
claims for Medicaid enrollees. I further characterized pre-post changes in telemedicine 
volumes by rurality, provider type and specialty, and condition category. Next, I 
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presented the average plan paid amounts in each year for telemedicine and non-
telemedicine services, in each procedure category. 
 
Assessing the Change in Mental Health and Non-Mental Health Services in the Medicaid 
Comparison Group Relative to the Medicare Comparison Group 
The MTA policy was originally introduced to the Minnesota Senate in the first 
quarter of 2015 ("Coverage of Telemedicine Services," 2015). Following this action, 
hospital groups and other media covered the components of the bill in various press 
releases (Browning, 2015; MHA, 2015). The media attention pertaining to the MTA 
policy in 2015, and its implementation in 2016 provides variation in exposure to the 
reimbursement policy based on the year and the patient’s coverage type. I examined the 
relationship between the introduction and implementation of the policy change and per 
capita telemedicine use, using a difference-in-differences (DID) model. Medicare 
enrollees in Minnesota served as the comparison group, as their reimbursement of 
telemedicine services did not change over this period. I assessed both years 2015 and 
2016 as separate post periods. I used the following specification for the DID analysis:   
(Eq. 1)  Yipt = 𝛽0 𝑋𝑖𝑡 + 𝛽1Medicaid + 𝛽2Medicaid X MTA+ µp + quarter*σp + 𝑦𝑡 + 𝑣ipt       
where the outcome 𝑌𝑖p𝑡 is the total number of services per person in each year. 
The model is also stratified by mental health services, which were already being 
reimbursed at parity in the state for physicians, and non-mental health services, which 
were more directly affected by the MTA. In Eq. 1, the variable Medicaid takes on the 
value of one if an individual is a Medicaid enrollee, and zero otherwise. MTA is in 
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indicator variable for whether the year is before or after the passage of the MTA. Each 
post-MTA passage year (2015, 2016) is interacted separately with the treatment group. 
The vector 𝑋𝑖𝑡 contains patient characteristics; these include patient sex, age, and 
presence of chronic conditions. Year and payer fixed effects are captured by yt and µp. I 
also included a payer-quarter time trend, represented by quarter*σp. The coefficient of 
interest 𝛽2 captures the association of the policy change and telemedicine use. I estimated 
an ordinary least squares (OLS) regression, adjusting standard errors in all models for 
within-plan serial correlation by clustering at the insurer level.  
Next, I evaluated the change in the number of in-person, and overall visits for 
mental health services from the pre to the post periods for Medicaid enrollees between 
the ages of 50 and 64 in a small towns and rural ZIP code, relative to the comparison 
group of Medicare enrollees. An increase in telemedicine visits, and a decrease in in-
person visits may suggest for instance, that telemedicine visits replaced in-person visits 
over the study period.  
The DID analysis relies on the assumption of parallel trends that in the absence of 
the MTA during study period, the difference in telemedicine visits between the treatment 
and comparison groups would have stayed the same over time. I showed the adjusted 
trends in mental health and non-mental health telemedicine visits per capita across both 
the treatment and comparison groups (Appendix Exhibit 4-2).  
  
4.4. Results  
Telemedicine in the Medicaid Population 
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From 2010 to 2016, telemedicine visits within the Medicaid population in MN 
increased from 972 to 4,490 total visits (Figure 4-1). Among all of the telemedicine 
visits, mental health conditions made up 70.3% of the total volume of telemedicine visits 
in 2010, and 82.5% of the total volume in 2016. Telemedicine visits as a percentage of all 
claims increased from 0.02% to 0.06% of all claims (Appendix Exhibit 4-3). 
Telemedicine users increased from 28.6 to 106.2 users per 10,000 enrollees, and nearly 
all telemedicine users used only one telemedicine service per week over the entire study 
period (Appendix Exhibit 4-4, Appendix Exhibit 4-5). Although the volume of 
telemedicine was concentrated primarily within metropolitan areas over the study period, 
telemedicine utilization as a proportion of all individuals within the region was largest in 
rural and micropolitan areas (Appendix Exhibit 4-6).  
The number of unique providers supplying telemedicine visits increased from 42 
in 2010 to 197 in 2016, an increase of 1.59 percent of all unique providers to 4.41 percent 
(Appendix Exhibit 4-7). Physician specialties however remained concentrated within 
mental health, nephrology, and endocrinology specialties between 2010 and 2016. 
Starting in 2015, family and internal medicine, sleep medicine, and rural and critical 
access medicine saw moderate increases in the number of claims submitted by each of 
these specialties. Nearly all telemedicine visits were provided by registered nurses and 
physicians prior to 2015. In 2015, there was a small increase in the number of NPs and 
LICSWs providing telemedicine visits, and in 2016, PAs providing telemedicine visits. 
Among the diagnosis categories for telemedicine visits, mental health conditions made up 
82.7% of all telemedicine services in 2016 (Appendix Exhibit 4-8). Visits for diabetes 
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started to grow in 2013, while the volume of claims for alcohol and other substance use 
disorders started in 2015, although levels in absolute terms remained low.  
The comparison of the observed average reimbursement amounts for each 
category of procedures showed that average reimbursements for telemedicine visits were 
higher in most years prior to the implementation of the MTA, compared to in-person 
visits (Figure 4-2). Average reimbursements for telemedicine visits decreased to match 
the rates for in-person services after the policy was implemented. For instance, across all 
categories of E&M procedures, there was a decrease in average reimbursements for 
telemedicine visits over time (Figure 4-2). Between psychiatry and non-psychiatry 
categories, average reimbursements for telemedicine were relatively higher for 
psychiatry specialties across all years (Figure 4-2).  
 
Change in Mental Health and Non-Mental Health Services in the Medicaid Comparison 
Group Relative to the Medicare Medicaid Comparison Group 
Among all claims with a primary diagnosis of a mental health condition and 
procedure, individuals in the treatment group in the pre-period (n = 53,502) are slightly 
more likely to be female, less likely to live in a metropolitan area, and have more chronic 
conditions compared to individuals in the comparison group (n = 222,909) (Figure 4-1). 
Pre and post period averages for treatment and comparison groups are shown in the 
appendix (Appendix Table 4-9). The number of telemental health services within the 
Medicaid enrollee sample increased relative to the Medicare comparison group in the 
first post-period in 2015 (0.012; p<0.001), as well as in 2016 (0.013, p<0.001) (Table 4-
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2). I found a very small and statistically significant change in the number of telemedicine 
visits per person for non-mental health services among the Medicaid enrollee sample 
relative to the Medicare enrollees comparison group in 2015 (0.006, p<0.01) but not in 
2016 (Table 2). Therefore the first post year of the MTA was not associated with a 
change in the number of per-person telemedicine visits for non-mental health services 
among Medicaid enrollees in small towns and rural areas. 
 
Expansions in In-Person Services  
While the number of telemental health services for the Medicaid treatment group 
in small towns and rural areas increased slightly relative to the Medicare comparison 
group in 2016 (Table 4-2), the number of mental and non-mental health care services 
delivered in-person did not change (Table 4-3). These results suggest that at the 
population-level, the MTA was not associated with overall expansions in health services 
in the first post year, in small towns and rural regions.  
 
4.5. Limitations 
 
There are a number of limitations in this study. First, the current data extract in 
the MN APCD contains missing data from certain payers in specific years. In the present 
analysis, these payers have been dropped from all years, which may bias the results. 
Future data extracts will contain a complete panel of payer data over all the study years. 
Second, among the present data, telemedicine encounters may not be fully captured over 
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the study period. Because the procedure code modifiers used to capture telemedicine 
visits are still relatively new, not all providers may uniformly bill for telemedicine visits. 
Additionally, it’s unclear whether the increases in the volume of telemedicine visits 
documented over the study period are due to actual increases in telemedicine visits 
supplied, or better billing practices as a result of changes in the reimbursement policy 
(MedPAC, 2016).  
Another limitation is that the trends in non-mental health telemedicine visits were 
significantly different between the treatment and comparison groups in the pre-period. 
Therefore, the parallel trends assumption may not have been satisfied for this particular 
DID analysis, and differing trends in non-mental health telemedicine visits between the 
comparison groups may have introduced bias to the results. 
Next, this study is focused only on telemedicine in Minnesota, and these 
conclusions may or may not generalize to other states. For instance, Minnesota already 
had a partial state parity law in place starting in 2006, which may have contributed to the 
relatively small increases in telemedicine use in 2016. Additionally, because this analysis 
is only focused on one state, I was unable to compare Medicaid enrollees in Minnesota 
with a similar population of enrollees in a different state. These two populations are 
different in terms of their demographics and comorbidities. To the extent that I did not 
adequately control for confounders related to both coverage and the outcomes of interest, 
using Medicare enrollees as a comparison group for Medicaid enrollees may have over or 
under-estimated the association of the MTA and telemedicine and non-telemedicine 
utilization. Within the Medicaid population, I also focused the regression analyses on 
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Medicaid individuals aged 55-64 only. These individuals may have a different propensity 
to use telemedicine compared to other Medicaid enrollee age brackets, and therefore may 
not generalize to the Medicaid population overall.  
Additionally, it is unclear why certain payers were already reimbursing for 
telemedicine services prior to the implementation of the MTA. Additional institutional 
knowledge from payers that is not available in the MN APCD, may provide insight as to 
why average reimbursements for telemedicine services decreased over time. 
Finally, this analysis was constrained by the availability of only one year of post 
data after the implementation of the MTA in the MN APCD. Further work will 
incorporate additional years of analyses.  
 
4.6. Discussion 
 
This study found increases in overall telemedicine visits over the study period 
2010 to 2016 among Medicaid enrollees, with sharper increases in the volume of visits 
after 2014. These increases remained even after looking at telemedicine as a proportion 
of all claims in each year. Mental health services made up an increasingly larger 
proportion of all telemedicine services between 2010 and 2016, prior to the enactment 
and implementation of the MTA, although these services were already being reimbursed 
at parity with in-person services for physicians. And while the law formally expanded the 
types of providers that can supply telemedicine services, the increase in telemedicine 
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claims was primarily concentrated within physicians, followed by RNs ("Physician and 
Professional Services," 2018).  
Surprisingly, observed telemedicine payment rates were actually higher before the 
MTA and decreased after the law. This result suggests that providers who were already 
supplying telemedicine services did not on average, experience an increase in 
reimbursements for telemedicine visits due to the MTA. It’s unclear however, whether 
the MTA improved reimbursement rates for providers who did not previously supply 
telemedicine services, since those reimbursements were not observed. For instance, 
providers receiving reimbursements below a certain threshold, may not have delivered or 
billed for telemedicine visits. Therefore, the observed level of reimbursement may have 
been a biased estimate of the actual reimbursement rate across all providers.   
I did find evidence that the parity law differentially increased telemedicine use for 
Medicaid patients relative to Medicare patients in 2015. For mental health visits, I found 
that telemedicine increased among Medicaid patients relative to Medicare patients in the 
first post year of the implementation of the MTA. I did not find any evidence however, 
that the MTA was associated with any increases in telemedicine for non-mental health 
services in 2016, nor any increases in in-person mental or non-mental health services. 
The increase in telemedicine visits in 2015 may be due to provider anticipatory effects of 
the MTA, or the endogeneity of the policy change, as providers may have lobbied for 
passage of the MTA. Additionally, vertically integrated health systems within the state 
may have increased investments in telemedicine prior to 2016, due to the forthcoming 
implementation of the MTA for both commercial and Medicaid populations.  
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Another unanticipated finding was that the increase in telemedicine visits only 
occurred for mental health services in the first year after the implementation of the MTA. 
There are a number of factors that may have contributed to this. First, the levels of 
investment may be higher to deliver telemedicine services in non-mental health 
specialties. Furthermore, the infrastructure for telemental visits may have already existed 
in health systems due to the 2006 parity law. Secondly, there may have also been 
increased consumer demand for telemental visits in response to various press releases 
about the law in 2015 (Browning, 2015).  
Around the enactment and implementation of the MTA, telemedicine use within 
the Medicare population grew slightly as well. These findings align with past studies that 
have documented a higher volume of telemedicine visits within the Medicare population 
in states with parity laws, even though Medicare enrollees are directly targeted by these 
policy changes (Mehrotra et al., 2017; Mehrotra et al., 2016; Neufeld et al., 2016). This 
suggests that the state parity law in MN may have had small spillover effects in the 
Medicare population, such that providers increasing telemedicine provision for Medicaid 
enrollees were also supplying more telemedicine visits to their Medicare patients.  
The conclusions drawn from this study suggest that overall, a telemedicine parity 
law may not be enough to motivate providers to supply telemedicine to Medicaid 
enrollees in small towns and rural areas for non-mental health conditions. Additionally, 
the parity law was not associated with increases in-person population-level utilization of 
health care services in these geographic areas, suggesting that telemedicine coverage 
policies may not lead to expansions in in-person services. Future work should explore 
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other policies that further incentivize providers and health systems to provide 
telemedicine, particularly to underserved populations, beyond simply providing 
reimbursement parity to in-person services (Park et al., 2018). 
In addition to varying reimbursements for telemedicine, further work may explore 
other legal barriers such as state licensure laws and credentialing, and data privacy and 
security issues, that may also limit the use of telehealth (Dorsey & Topol, 2016; Martinez 
et al., 2018). Substantial social and cultural barriers for both patients and providers may 
hinder further uptake as well (Dorsey & Topol, 2016). For patients, seeking a new form 
of care may require additional education and assistance form health care providers. For 
providers, there may be an unwillingness to adopt new technology paradigms, as well as 
the perceived threat of telemedicine poaching patients from existing providers (Rogove, 
McArthur, Demaerschalk, & Vespa, 2012).  
 
4.7. Conclusion 
 
The MTA, a statewide parity law in Minnesota, was associated with modest 
increases in telemental use among Medicaid enrollees relative to a comparison group of 
Medicare enrollees in the first year after the implementation of the MTA. While 
reimbursements for telemedicine and in-person visits were very similar in 2016, 
telemedicine reimbursements decreased on average, for providers already supplying 
telemedicine visits. A telemedicine parity law alone therefore, may not be sufficient for 
improving the use of telemedicine in underserved areas.  
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Figure 4-1. Volume of Telemedicine Visits for Medicaid Enrollees, 2010-2016 
Note: Both real-time and store-and-forward telemedicine encounters are included. All 
Medicaid enrollee telemedicine encounters are included. All mental health conditions are 
identified based on the primary ICD-9 or ICD-10 code on the claim (Appendix 1).  
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Figure 4-2. Average Reimbursements for Common Procedures for Telemedicine and In-
person Services 
 
Evaluation and Management Procedure 99213 
 
 
Note: Only encounters with a provider type and specialty are included. Both real-time 
and store-and-forward telemedicine encounters are included. Fee-for-service and 
managed care plans are based on MN APCD product types. Only years where there are 
over 50 telemedicine encounters are included.  
Note: Encounters with a psychiatric specialty are excluded. Both real-time and store-and-
forward telemedicine encounters are included. All provider types are included. Fee-for-
service and managed care plans are based on MN APCD product types. Only years where 
there are over 50 telemedicine encounters are included. 
 
 
Fee-for-service Plans  Managed Care Plans 
0
20
40
60
2013 2014 2015 2016
P
la
n
 P
ai
d
 A
m
o
u
n
ts
, 
$
Psychiatry Specialties, Physician
Telemedicine In-person
0
20
40
60
80
2013 2014 2015 2016
P
la
n
 P
ai
d
 A
m
o
u
n
ts
, 
$
Psychiatry Specialties, Physician
Telemedicine In-person
0
20
40
60
2013 2014 2015 2016P
la
n
 P
ai
d
 A
m
o
u
n
ts
, 
$
Non-Psychiatry Specialties (All 
Provider Types Included)
Telemedicine In-person
0
20
40
60
80
2013 2014 2015 2016P
la
n
 P
ai
d
 A
m
o
u
n
ts
, 
$
Non-Psychiatry Specialties (All 
Provider Types Included)
Telemedicine In-person
121 
 
 
 
Evaluation and Management Procedure 99214 
 
 
 
 
Note: Only encounters with a provider type and specialty are included. Both real-time 
and store-and-forward telemedicine encounters are included. Fee-for-service and 
managed care plans are based on MN APCD product types. Only years where there are 
over 50 telemedicine encounters are included. 
 
Note: Encounters with a psychiatric specialty are excluded. Both real-time and store-and-
forward telemedicine encounters are included. All provider types are included. Fee-for-
service and managed care plans are based on MN APCD product types. Only years where 
there are over 50 telemedicine encounters are included. 
 
Fee-for-service Plans  Managed Care Plans 
0
20
40
60
80
100
2013 2014 2015 2016P
la
n
 P
ai
d
 A
m
o
u
n
ts
, 
$
Psychiatry Specialties, Physician
Telemedicine In-person
0
20
40
60
80
100
120
2014 2015 2016P
la
n
 P
ai
d
 A
m
o
u
n
ts
, 
$
Psychiatry Specialty, Physician
Telemedicine In-person
0
20
40
60
80
2015 2016P
la
n
 P
ai
d
 A
m
o
u
n
ts
, 
$
Non-Psychiatry Specialties, All 
Providers
Telemedicine In-person
0
50
100
150
2015 2016P
la
n
 P
a
id
 A
m
o
u
n
ts
, 
$
Non-Psychiatry Specialties, All 
Providers
Telemedicine In-person
122 
 
 
 
Psychotherapy Procedure 90833 
 
 
Note: All provider types and specialties are included. Both real-time and store-and-
forward telemedicine encounters are included. Fee-for-service and managed care plans 
are based on MN APCD product types. Only years where there are over 50 telemedicine 
encounters are included. 
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Table 4-1. Descriptive Statistics for Medicaid and Medicare Enrollee Comparison Groups 
 Pre intervention 
Variable Medicaid Medicare 
Age 58.96 67.49 
Gender -Female 54.05 52.98 
Probability of High User (Categories 
1-4) 
2.08 1.63 
Asthma 5.62 13.73 
Bipolar 4.04 0.42 
Congestive Heart Failure 3.86 2.58 
Chronic Obstructive Pulmonary 
Disorder 
9.62 4.79 
Depression 20.96 5.50 
Diabetes 24.63 19.23 
Hypertension 32.09 32.62 
Ischemic Heart Disease 7.94 8.15 
Low Back Pain 22.78 21.90 
Renal Failure 4.23 3.29 
Rheumatoid Arthritis 1.66 1.55 
Number of chronic conditions 4.30 3.33 
Lives in a rural area (%) 50.54 54.49 
N  53,502 222,909 
Note: Both real-time and store-and-forward telemedicine encounters are included for 
Medicare and Medicaid comparison groups. Medicaid enrollees aged 50-64 and Medicare 
enrollees aged 65-70, living in small towns and rural areas are included in the comparison 
groups. 
 
124 
 
Table 4-2. Association between Statewide Parity Policy Enactment and Implementation and Telemedicine Use for Mental 
and Non-Mental Health Services, Small Towns and Rural Regions 
Telemedicine Visits per Person for 
Mental Health Services 
Coeff. SE p-value Coeff. SE p-value 
Post (2015) * Treatment 0.012 0.005 0.017 0.012 0.005 0.025 
Post (2016) * Treatment 0.013 0.002 0.000 0.013 0.002 0.000 
Payer-product Fixed Effects and Year 
Fixed Effects 
x x x    
Payer-product Fixed Effects, Year Fixed 
Effects, Product-Quarter Time Trend 
   x x x 
Telemedicine Visits per Person for Non-
Mental Health Services 
Coeff. SE p-value Coeff. SE p-value 
Post (2015) * Treatment 0.006 0.002 0.001 0.006 0.002 0.001 
Post (2016) * Treatment 0.003 0.002 0.187 0.003 0.002 0.195 
Payer-product Fixed Effects and Year 
Fixed Effects 
x x x    
Payer-product Fixed Effects, Year Fixed 
Effects, Product-Quarter Time Trend 
   x x X 
N 407,801 
Note: Medicaid enrollees aged 50-64 and Medicare enrollees aged 65-70, living in small towns and rural areas are included in the 
comparison groups. Only claims where the primary diagnosis is for a mental health condition and procedure for mental health service 
(Appendix exhibit 1) are included in the analysis of telemedicine visits for mental health services. Only claims without a primary 
diagnosis is for a mental health condition nor a procedure for mental health service (Appendix exhibit 1) are included in the analysis 
of telemedicine visits for non-mental health services. Both real-time and store-and-forward telemedicine encounters are included. All 
analyses are clustered at the plan payer level. Individuals are assigned to a small town or rural region based on the plurality of their 
ZIP codes and the ZIP code RUCA category.  
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Table 4-3. Association between Statewide Parity Policy Enactment and Implementation and In-person Use for Mental Health and 
Non-mental Health Services, Small Towns and Rural Regions 
In-Person Mental Health Visits per 
Person 
Coeff. SE p-value Coeff. SE p-value 
Post (2015) * Treatment 0.045 0.062 0.478 0.010 0.056 0.857 
Post (2016) * Treatment -0.010 0.115 0.935 -0.023 0.102 0.825 
Payer-product Fixed Effects and 
Year Fixed Effects 
X x X    
Payer-product Fixed Effects, Year 
Fixed Effects, Product-Quarter Time 
Trend 
   x x X 
In-Person Non-Mental Health Visits 
per Person 
Coeff. SE p-value Coeff. SE p-value 
Post (2015) * Treatment 2.218 1.038 0.043 1.715 0.949 0.084 
Post (2016) * Treatment -1.341 1.651 0.425 -1.533 1.542 0.331 
Payer-product Fixed Effects and 
Year Fixed Effects 
X x x    
Payer-product Fixed Effects, Year 
Fixed Effects, Product-Quarter Time 
Trend 
   x x X 
N 407,801 
Note: Medicaid enrollees aged 50-64 and Medicare enrollees aged 65-70, living in small towns and rural areas are included in the 
comparison groups. Only claims where the primary diagnosis is for a mental health condition and procedure for mental health service 
(Appendix exhibit 1) are included in this analysis. All analyses are clustered at the plan payer level. Individuals are assigned to a small 
town or rural region based on the plurality of their ZIP codes and the ZIP code RUCA category. 
126 
 
Appendix Exhibit 4-1. ICD-9 and ICD-10 Codes Used to Classify Mental Health 
Conditions 
ICD-9 
Mental Health Disorders 290-319 
290-294 Organic Psychotic Conditions 
295-299 Other Psychoses 
300-316 
Neurotic Disorders, Personality Disorders, And Other Nonpsychotic 
Mental Disorders 
317-319 Intellectual Disabilities 
    ICD 10 
F00–F09  Organic, including symptomatic, mental disorders 
F10–F19 Mental and behavioral disorders due to psychoactive substance abuse 
F20–F29 Schizophrenia, schizotypal, and delusional disorders 
F30–F39 Mood disorders, depression, and bipolar disorders 
F40–F49 Neurotic, anxiety, stress-related, and somatoform disorders 
F50–F59 
Behavioral syndromes associated with physiological disturbances and 
physical factors 
F60–F69 Disorders of adult personality and behaviors 
F70–F79 Intellectual disabilities 
F80–F89 Pervasive and specific developmental disorders 
F90–F98 
Behavioral and emotional disorders with onset usually occurring in 
childhood and adolescence 
F99 Unspecified mental disorder 
CPT Procedure Codes for Mental Health Services 
90816 90801 
90817 90802 
90818 90804 
90819 90805 
90820 90806 
90821 90807 
90822 90808 
90823 90809 
90824 90810 
90825 90811 
90826 90812 
90827 90813 
90828 90814 
90829 90815 
90830 90872 
90835 90875 
90841 90876 
90842 90880 
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90843 90882 
90844 90885 
90845 90887 
90846 90889 
90847 90899 
90848 90791 
90849 90792 
90853 90785 
90855 90832 
90857 90833 
90862 90834 
90865 90836 
90867 90837 
90868 90838 
90839 90840 
99211 99201 
99212 99202 
99213 99203 
99214 99204 
99215 99205 
Note: Source for all ICD-9 codes - http://www.icd9data.com/2013/Volume1/290-
319/default.htm. Source for all ICD-10 codes - 
https://www.icd10data.com/ICD10CM/Codes/F01-F99 
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Appendix Exhibit 4-2. Adjusted Telemedicine Use per Capita for Mental Health Services 
by Medicaid and Medicare Comparison Enrollees 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Both real-time and store-and-forward telemedicine encounters are included. 
Medicaid enrollees aged 50-64 and Medicare enrollees aged 65-70, living in small towns 
and rural areas are included in the comparison groups. Only claims where the primary 
diagnosis is for a mental health condition and the procedure code pertains to a 
professional service for mental health (Appendix exhibit 1) are included. The black line 
in the exhibit denotes the enactment of the MTA. The green line denotes its 
implementation. 
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Note: Both real-time and store-and-forward telemedicine encounters are included. 
Medicaid enrollees aged 50-64 and Medicare enrollees aged 65-70, living in small towns 
and rural areas are included in the comparison groups. Only claims without a primary 
diagnosis is for a mental health condition and without a procedure code pertaining to a 
professional service for mental health (Appendix exhibit 1) are included. The black line 
in the exhibit denotes the enactment of the MTA. The green line denotes its 
implementation. 
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Appendix Exhibit 4-3. Telemedicine Claims as a Percentage of all Claims for Medicaid 
Enrollees 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Both real-time and store-and-forward telemedicine encounters are included. Only 
Medicaid claims (all ages) for telemedicine are included in this exhibit. 
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Appendix Exhibit 4-4. Telemedicine Users as a Proportion of all Enrollees with a Claim 
during the Year 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Both real-time and store-and-forward telemedicine encounters are included. Only 
Medicaid enrollees (all ages) with one or more medical claims during the calendar year 
are included in this exhibit.  
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Appendix Exhibit 4-5. Telemedicine Use per Calendar Week 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Both real-time and store-and-forward telemedicine encounters are included. Only 
Medicaid claims (all ages) for telemedicine are included in this exhibit. 
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Appendix Exhibit 4-6. Volume and Proportion of Telemedicine Visits by Rurality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Both real-time and store-and-forward telemedicine encounters are included. Only 
Medicaid enrollees (all ages) with one or more medical claims during the calendar year 
are included in this exhibit. 
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Appendix Exhibit 4-7. Provider Specialty and Provider Types Delivering Telemedicine 
Visits  
2010 2011 2012 2013 2014 2015 2016 
Specialty 
      
 
Family and Internal 
Medicine 
-- -- -- -- 63 208 250 
Mental Health 617 550 565 862 1109 2192 2305 
Nephrology and 
Endocrinology 
144 149 143 146 174 267 274 
Rural and Critical 
Access 
38 24 -- 28 64 97 133 
Neurology -- -- 28 144 161 159 183 
Sleep Medicine 27 20 -- -- 53 73 43 
Other -- -- 26 -- 56 88 78 
Total Telemedicine 
Claims 
865 762 805 1228 1682 3084 3266 
Provider Type 
      
 
MD/DO 742 706 775 1281 1540 2512 2419 
NP 38 -- 24 29 120 351 475 
PA -- -- -- -- -- 41 138 
PhD -- 49 71 74 66 86 75 
LICSW -- -- -- -- 25 55 30 
RN 26 25 39 119 108 171 279 
Total Telemedicine 
Claims 
827 800 914 1533 1893 3235 3512 
Percentage of Total 
Unique Providers 
1.59 2.25 2.79 3.39 3.86 4.75 4.41 
Note: Both real-time and store-and-forward telemedicine encounters are included. Only 
Medicaid claims (all ages) for telemedicine are included in this exhibit. 
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Appendix Exhibit 4-8. Diagnosis Categories for Telemedicine Visits  
2010 2011 2012 2013 2014 2015 2016 
Diagnosis 
Categories 
       
Alcohol and other 
Substance Use 
Disorders 
-- -- -- -- -- -- 40 
Mood and Anxiety 
Disorders 
495 488 535 827 1218 2397 2603 
Dementia and Other 
Disorders 
48 28 29 105 92 139 150 
Schizophrenia and 
Other Psychotic 
Disorders 
133 127 181 365 386 590 700 
Other Mental Health 
Disorders 
-- -- -- 58 89 206 222 
Chronic Kidney 
Disease and End 
Stage Renal Disease 
152 149 144 143 166 252 281 
Diabetes and 
Complications 
-- -- -- 20 39 37 39 
Other 123 84 141 239 368 443 368 
Total Claims 972 895 1060 1767 2374 4146 4490 
Note: Both real-time and store-and-forward telemedicine encounters are included. Only 
Medicaid claims (all ages) for telemedicine are included in this exhibit. The AHRQ 
Clinical Classification Software is used to determine diagnoses categoris. Only the 
primary diagnosis is used for the diagnosis categories. 
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5. Discussion 
 
These three papers collectively contribute to the empirical literature on 
telemedicine. In the first paper, I characterized the patterns of telemedicine use in 
Minnesota. Among the trends in telemedicine use, I found that increasingly, patients are 
reaching their providers through convenient care, or direct-to-consumer (DTC) 
telemedicine services. In the second paper, I then evaluated the association of using DTC 
telemedicine and a number of follow-up outcomes. Finally, I examined how a state 
payment policy for telemedicine may be associated with the provision of telemedicine 
services.  
In the first paper, I found that in the period 2010–15, telemedicine visits increased 
from 11,113 to 86,238, and rates of use varied extensively by coverage type and rurality. 
In metropolitan areas, telemedicine visits were primarily DTC services provided by nurse 
practitioners or physician assistants and covered by commercial insurance. In 
nonmetropolitan areas, telemedicine use consisted mainly of real-time provider-initiated 
services delivered by physicians to publicly insured populations. These results suggest 
that coverage policies and provider reimbursement are important factors in determining 
which patients receive telemedicine and which types of telemedicine are provided. 
In the analysis of DTC telemedicine visits in Minnesota of commercially insured, 
non-elderly females treated for UTIs, I found that the initiation of health insurance 
coverage for DTC telemedicine was associated with a 17 percentage point increase in 
telemedicine-initiated episodes of UTI. An initial DTC telemedicine visit in this study 
sample was associated with reductions in the overall number of services, prescriptions for 
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antibiotics of concern, and total spending during a 30-day episode of care. These results 
suggest that for a commercially-insured population, DTC telemedicine services may 
reduce utilization of specific health care services and medical spending for UTIs, while 
maintaining a comparable quality of care to in-person services. 
In the final analysis, I examined how a telemedicine payment parity law affecting 
Medicaid enrollees in Minnesota may have contributed to the growth in telemedicine use. 
Average reimbursements for telemedicine visits were similar with those of in-person 
visits after the statewide parity law went into effect, but for common telemedicine 
procedures, observed average reimbursements for telemedicine visits actually decreased 
over time. Over the study period, in nonmetropolitan areas, there were modest increases 
in telemedicine use for mental health services, and no increases in telemedicine use for 
non-mental health services compared to a comparison group of Medicare enrollees. 
Therefore, a telemedicine parity law alone, may not be sufficient for improving the use of 
telemedicine in underserved areas. 
These studies taken together, lay the groundwork for future research to examine 
other conditions, procedures, and populations for which telemedicine can improve the 
delivery of care. For instance, from paper 1, the patterns of telemedicine use can also be 
characterized using other state all-payer claims databases. In papers 2 and 3, we focused 
on a specific patient population and condition, but these analyses should be replicated and 
extended in other states and coverage populations, and for various other acute and 
chronic care conditions.  
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The area of telemedicine is still evolving, as new models of care incorporating 
virtual health continue to proliferate. The growing body of evidence on telemedicine will 
help inform policymakers, payers, and providers as to when telemedicine may be a 
comparable or better alternative to conventional care, particularly in rural areas and for 
underserved populations.  
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